AU2006269824A1 - Chaperonin 10-induced immunomodulation - Google Patents

Description

WO 2007/006095 PCT/AU2006/000980 -1 Chaperonin 10-induced Immunomodulation Field of the Invention The present invention relates generally to the use of chaperonin 10 in the 5 modulation of Toll-like receptor signalling, in particular TLR2, TLR3, TLR4, TLR7 and TLR9 signalling, and to methods and compositions for the treatment of diseases, including but not limited to viral and bacterial infections, inflammatory diseases and autoimmune diseases, via chaperonin 10-induced modulation of such signalling. o10 Background of the Invention A central component of host defence systems against invading bacterial, fungal, yeast and viral pathogens involves the successful recognition of the pathogen, or components thereof, by cellular receptors which induce a signalling cascade resulting in stimulation of the immune system and the production of various cytokines. One family of 15 receptors which plays a key role in this line of defence is the Toll-like receptor (TLR) family. TLRs are expressed on immune cells including monocytes, macrophages, dendritic cells, B cells and granulocytes, and a variety of other cell types including endothelium and epithelium. TLR activation by pathogens, or by molecules derived therefrom, induces intracellular signalling that primarily results in activation of the 20 transcription factor NF-KB (Beg, 2002, Trends Inmunol 23:509-12.) and modulation of cytokine production. However, a series of other pathways can also be triggered, including p 3 8 mitogen activated kinase, c-Jun-N-terminal kinase and extracellular signal related kinase pathways (Flohe et al., 2003, J Immunol 170:2340-2348; Triantafilou and Triantafilou, 2002, Trends Immunol 23:301-304). 25 Type I interferons, principally IFNat and IFN3, are major contributors in the immune response to bacterial and viral infections. The primary source of type I interferons following such infections are plasmacytoid dendritic cells (PDCs), a specialised subpopulation of peripheral blood mononuclear cells. PDCs express the Toll like receptors TLR7 and TLR9 and it is TLR7/TLR9 stimulation that is responsible for 30 PDC activation and the production of large quantities of type I interferons. A range of pathogen-derived factors are capable of selectively stimulating different TLRs. One of the best characterised of these is lipopolysaccharide (LPS), a glycolipid derived from the outer membrane of Gram-negative bacteria, which is an agonist of TLR4. TLR2 recognizes lipoteichoic acid (LTA), petidoglycan (PGN) and lipopeptide, WO 2007/006095 PCT/AU2006/000980 -2 TLR3 recognises double-stranded RNA, typically of viral origin; TLR 7 recognises viral single-stranded RNA and TLR9 recognises unmethylated CpG dinucleotides, typically within bacterial and viral DNA. TLRs can also be stimulated by a variety of synthetic agonists, for example polyl:C (polyinosinic-polysytidilic acid) in the case of TLR3, 5 imidazoquinolines such as resiquimod (R848) and imiquimod in the case of TLR7 and CpG-rich oligonucleotides in the case of TLR9. The elucidation of mechanisms for the modulation of TLR signalling and modulation of TLR-stimulated cytokine and chemokine production will provide avenues for the development of therapeutic approaches to the treatment of a variety of diseases and 10 conditions, including viral and bacterial diseases. Mammalian chaperonin 10 (Cpnl 0), also known as heat shock protein 10 (Hspl 10), is typically characterised as a mitochondrial 'molecular chaperone' protein involved in protein folding together with chaperonin 60 (Cpn60; Hsp60). CpnlO is a homologue of the bacterial protein GroES. GroES and CpnlO0 oligomerise into seven member rings that 15is bind as a lid onto a barrel-like structure that comprises fourteen GroEL or seven Hsp60 molecules, which tether denatured proteins to the complex. CpnlO is also frequently found at the cell surface (Belles et al., 1999, Infect Immun 67:4191-4200) and in the extracellular fluid (Shin et al., 2003, JBiol Chemin 278: 7607-7616). However Cpnl0 has also been shown to possess immunosuppressive activity in 20 experimental autoimmune encephalomyelitis, delayed type hypersensitivity and allograft rejection models (Zhang et al., 2003, J Neurol Sci 212:37-46; Morton et al., 2000, Immnunol Cell Biol 78:603-607). Previously, the present inventors have also demonstrated that in the presence of TLR4 and TLR2 agonists (LPS and PAM 3 CysSK 4 , respectively), CpnlO reduces TLR4 25 and TLR2-stimulated NF-KB activation, reduces TNF-a and RANTES secretion, whilst increasing IL-10 secretion in a dose-dependent manner (Johnson et al., 2005, JBiol Chem 280:4037-4047; International Patent Application No. PCT/AU2005/000041; WO2005/067959, the disclosures of which are incorporated herein by reference). The inventors have now surprisingly found that CpnlO also modulates signalling 30 by TLR3, TLR7 and TLR9. Cpnl0 is shown herein to dose-responsively enhance the production of IFNo and IFN/f in the presence of a TLR3-specific ligand, and to reduce NF-kB activation in the presence of TLR7- and TLR9-specific ligands. Moreover, the inventors have surprisingly shown that Cpn10, but not Cpn60 or GroES, associates with TLRs in activation clusters at the cell surface, with such activation clusters modulating 35 TLR signalling.

WO 2007/006095 PCT/AU2006/000980 -3 Summary of the Invention According to a first aspect of the present invention, there is provided a method for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, wherein said method comprises administering an effective amount of chaperonin 5 10, wherein Toll-like receptor signalling involves association of the chaperonin 10 with a Toll-like receptor in an activation cluster. According to a second aspect of the present invention, there is provided a method for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, wherein said method comprises administering an effective amount of at 10 least one antagonist of chaperonin 10, wherein Toll-like receptor signalling involves association of the chaperonin 10 with a Toll-like receptor in an activation cluster, and wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster. The activation cluster may be located on the surface of a cell. 15 The activation cluster may comprise chaperonin 10, a Toll-like receptor, and optionally, at least one other molecule. The at least one other molecule may comprise a Toll-like receptor agonist. In one embodiment, the activation cluster comprises chaperonin 10, TLR2 and lipoteichoic acid (LTA). 20 In an additional embodiment, the activation cluster comprises chaperonin 10, TLR3 and double-stranded RNA. In another embodiment, the activation cluster comprises chaperonin 10, TLR4 and LPS. In a further embodiment, the activation cluster comprises chaperonin 10, TLR7 and 25 single-stranded RNA. In a still further embodiment, the activation cluster comprises chaperonin 10, TLR9 and DNA comprising a CpG motif. The chaperonin 10 may be a naturally-derived, recombinantly produced or synthetically produced chaperonin 10. The chaperonin 10 may be of eukaryotic origin. 30 The chaperonin 10 may be human chaperonin 10. The chaperonin 10 may comprise the polypeptide sequence as set forth in SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3. The chaperonin 10 may be acetylated or non acetylated. The chaperonin 10 may be administered in the form of a polynucleotide encoding 35 chaperonin 10. The polynucleotide encoding chaperonin 10 may be located in a genetic WO 2007/006095 PCT/AU2006/000980 -4 construct, operably linked to a promoter. The polynucleotide may comprise the sequence as set forth in SEQ ID NO:4. The method may further comprise the administration of at least one additional agent. The agent may be an immunomodulator. The immunomodulator may be a type I 5 interferon such as IFNc or IFNP3. According to a third aspect of the present invention there is provided a method for treating or preventing a disease or condition in a subject, wherein said method comprises administering to the subject an effective amount of chaperonin 10, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of 1o the activation cluster is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition. According to a fourth aspect of the present invention there is provided a method for the treatment or prevention of a disorder in the subject, wherein said method comprises administering to the subject an effective amount of at least one antagonist of chaperonin 15 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or condition. The disease or condition may be selected from the group comprising viral, fungal, 20 yeast or bacterial infections, acute or chronic inflammatory diseases including septic shock, inflammatory bowel disease, arthritis, psoriasis, heart disease, atherosclerosis, chronic pulmonary disease, cachexia, multiple sclerosis, GVHD and cancer. In one embodiment, the chaperonin 10 regulates LTA-induced TLR2 signalling. The chaperonin 10 may modulate TLR2-induced immunomodulator production and/or 25 secretion. In an additional embodiment, the chaperonin 10 regulates double-stranded RNA induced TLR3 signalling. The chaperonin 10 may modulate TLR3-induced immunomodulator production and/or secretion. In another embodiment, the chaperonin 10 regulates LPS-induced TLR4 signalling. 30 The chaperonin 10 may modulate TLR4-induced immunomodulator production and/or secretion. In a further embodiment, the chaperonin 10 regulates viral single-stranded RNA induced TLR7 signalling. The chaperonin 10 may modulate TLR7-induced immunomodulator production and/or secretion.

WO 2007/006095 PCT/AU2006/000980 -5 In a still further embodiment, the chaperonin 10 regulates CpG motif-induced TLR9 signalling. The chaperonin 10 may modulate TLR9-induced immunomodulator production and/or secretion. The chaperonin 10 may be a naturally-derived, recombinantly produced or 5 synthetically produced chaperonin 10. The chaperonin 10 may be of eukaryotic origin. The chaperonin 10 may be human chaperonin 10. The chaperonin 10 may comprise the polypeptide sequence as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3. The chaperonin 10 may be acetylated or non acetylated. 10 The chaperonin 10 may be administered in the form of a polynucleotide encoding chaperonin 10. The polynucleotide encoding chaperonin 10 may be located in a genetic construct, operably linked to a promoter. The polynucleotide may comprise the sequence as set forth in SEQ ID NO:4. The method may further comprise the administration of at least one additional 15is agent. The agent may be an immunomodulator. The immunomodulator may be a type I interferon such as IFNcc or IFNP. According to a fifth aspect of the present invention there is provided a composition when used for the treatment or prevention of a disease or condition, the composition comprising chaperonin 10 together with at least one pharmaceutically acceptable carrier, 20 diluent or adjuvant, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition. The composition may further comprise at least one agonist of a Toll-like receptor. 25 The composition may further comprise at least one immunomodulator such as a type I interferon. According to a sixth aspect of the present invention there is provided a composition when used for the treatment or prevention of a disease or condition, the composition comprising at least one antagonist of chaperonin 10, wherein the antagonist prevents 30 chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or condition. According to a seventh aspect of the present invention there is provided the use of chaperonin 10 for the manufacture of a medicament for the treatment or prevention of a 35 disease or condition, wherein the chaperonin 10 associates with a Toll-like receptor in an WO 2007/006095 PCT/AU2006/000980 -6 activation cluster, and wherein formation of the activation cluster is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition. According to an eighth aspect of the present invention there is provided the use of 5 an antagonist of chaperonin 10 for the manufacture of a medicament for the treatment or prevention of a disease or condition, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establisluhment and/or progression of the disease or condition. to According to a ninth aspect of the present invention there is provided a method for modulating the production and/or secretion of one or more immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said method comprises administering an effective amount of chaperonin 10, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation 15is cluster is associated with modulation of the production and/or secretion of the one or more immunomodulators. According to a tenth aspect of the present invention there is provided a method for modulating the production and/or secretion of one or more immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said method comprises 20 administering an effective amount of an antagonist of chaperonin 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with modulation of the production and/or secretion of the one or more immunomodulators. 25 The immunomodulator may be, for example, TNF-ac, IL-13, IL-6, IL-10, IL-12 or a type I interferon. The type I interferon may be IFNu or IFNP. The above aspects and embodiments contemplate the use of wild-type and modified forms of chaperonin 10, as well as full-length chaperonin 10 polypeptides and fragments or derivatives thereof retaining immunomodulatory activity. 30 Definitions In the context of this specification, the term "comprising" means "including principally, but not necessarily solely". Furthermore, variations of the word WO 2007/006095 PCT/AU2006/000980 -7 "comprising", such as "comprise" and "comprises", have correspondingly varied meanings. As used herein the terms "treatment", "treating" and variations thereof, refer to any and all uses which remedy a disease state or symptoms, prevent the establishment of 5 disease, or otherwise prevent, hinder, retard, ameliorate or reverse the progression of disease or other undesirable symptoms in any way whatsoever. As used herein the term "effective amount" includes within its meaning a non toxic but sufficient amount of an agent or compound to provide the desired therapeutic or prophylactic effect. The exact amount required will vary from subject to subject 1o depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact "effective amount". However, for any given case, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only 15 routine experimentation. The term "polypeptide" means a polymer made up of amino acids linked together by peptide bonds. The terms "polypeptide" and "protein" are used interchangeably herein, although for the purposes of the present invention a "polypeptide" may constitute a portion of a full length protein. Polypeptides may also include, but are not limited to, 20 fragments, analogues, variants and derivatives thereof. Such fragments, analogues, variants and derivatives thereof may share a particular structural and/or functional similarity with the polypeptide. The term "polynucleotide" as used herein refers to a single- or double-stranded polymer of deoxyribonucleotide, ribonucleotide bases or known analogues or natural 25 nucleotides, or mixtures thereof. Within the scope of the term "polynucleotide" is included the reverse complement of the polynucleotide, and fragments, analogues, variants and derivatives of the polynucleotide, as well as any other polynucleotide that hybridizes to the polynucleotide under conditions of high stringency. As used herein the terms "modulating", "modulates" and variations thereof refer to 30 increasing or decreasing the level of activity, production, secretion or functioning of a molecule in the presence of a particular modulatory molecule or agent of the invention compared to the level of activity, production, secretion or other functioning thereof in the absence of the modulatory molecule or agent. These terms do not imply quantification of the increase or decrease. The modulation may be of any magnitude sufficient to produce s35 the desired result and may be direct or indirect.

WO 2007/006095 PCT/AU2006/000980 -8 The term "immunomodulator" as used herein includes, but is not limited to, a molecular mediator secreted by one or more cell types and which plays a role in the initiation, activation, maintenance, enhancement, maturation, inhibition, suppression or augmentation of an immune response. 5 The term "activation cluster" as used herein refers to an association of molecules that function to produce a biological signal. Typically, the biological signal may comprise modulation of an immune response, and in particular may involve modulation of Toll-like receptor signalling as part of this modulation process. An activation cluster may associate, for example, on the surface of a cell or within endosomes, and may comprise, for 10 example, chaperonin 10 together with a Toll-like receptor agonist and a Toll-like receptor. Other molecules may also associate as part of an activation cluster, including, but not limited to, CD14. Brief Description of the Drawings 15 The present invention will now be described, by way of non-limiting example only, with reference to the accompanying drawings. Figure 1. Secretion of IFNI3 (pg/ml) into supernatant of RAW264.7 cells following stimulation with 100 pg/ml polyl:C for 23 hours and in the presence of 10 - 200 pg/ml recombinant human Cpnl 0, added 2 hours pre-stimulation. Results shown are from 20 duplicate experiments. Figure 2. Secretion of type I interferons (IU/ml) into supernatant of RAW264.7 cells following stimulation with either 100 ng/ml re-purified LPS or 100 pg/ml polyl:C in the presence of 10 - 100 pg/ml recombinant human Cpnl0, added 2 hours pre-stimulation. Figure 3. NF-icB activation (x-fold) in HEK293 cells following transfection with 25 TLR7/TLR4-expressing construct and an NF-xB-luciferase reporter construct, in the presence (open squares) or absence (filled squares) of 50 pLg/ml recombinant human Cpnl0 (added simultaneously with agonist). Cells were stimulated with either phorbol 12-myristate 13-acetate (PMA; protein kinase C activator), R848 (R848; TLR7 agonist), CpG oligonucleotide (CpG; TLR9 agonist) or re-purified lipopolysaccharide (LPS; TLR4 30 agonist). Figure 4. NF-cB activation (x-fold) in HEK293 cells following transfection with TLR9-expressing construct and an NF-KB-luciferase reporter construct, in the presence (open squares) or absence (filled squares) of 50 pg/ml recombinant human Cpnl0 (added simultaneously with agonist). Cells were stimulated with either phorbol 12-myristate 13 35 acetate (PMA; protein kinase C activator), R848 (R848; TLR7 agonist), CpG WO 2007/006095 PCT/AU2006/000980 -9 oligonucleotide (CpG; TLR9 agonist) or re-purified lipopolysaccharide (LPS; TLR4 agonist). Results for two independent clones are presented (A and B). Figure 5. Effect of recombinant human Cpnl0 concentration (12.5 pg/ml, 25 pLg/ml, 50 pg/ml and 100 tg/ml) on NF-icB activation (presented as A, luciferase units and 5 B, relative luciferase units) in HEK293 cells transfected with TLR9-expressing construct and an NF-lcB-luciferase reporter construct in the presence of CpG DNA (Cpnl0 added simultaneously with agonist). Figure 6. A. TNF-c release (ng/ml) from human peripheral blood mononuclear cells (PBMCs) stimulated with re-purified lipopolysaccharide (LPS) and in the presence io of varying concentrations of recombinant human Cpnl0 (1 gig/ml, 10 pgg/ml or 50 pg/ml) or in the absence of Cpnl0 (added simultaneously with agonist). B. As for A, except PBMCs were first depleted ofplasmacytoid dendritic cells (PDCs). Figure 7. A. IL-10 release (ng/ml) from human peripheral blood mononuclear cells (PBMCs) stimulated with re-purified lipopolysaccharide (LPS) and in the presence 15is of varying concentrations of recombinant human Cpnl0 (1 pg/ml, 10 pg/ml or 50 pg/mnl) or in the absence of Cpnl0. B. As for A, except PBMCs were first depleted of plasmacytoid dendritic cells (PDCs). Figure 8. CpnlO does not reduce NF-icB activation through Poly(I:C) in the RAW264-pNifty2-LUC cell line. 20 Figure 9. CpnlO dose-responsively promotes production of Type I IFNs in RAW264.7 cells stimulated by LPS (predominantly IFN-P3) or Poly(I:C) (predominantly IFN-c) for 24 hours. Figure 10. CpnlO dose-responsively promotes production of IFNt at the transcriptional level in RAW264.7 cells stimulated with Poly(I:C). Potentiation of IFNO 25 in the presence of Cpn10 is also seen in RAW264.7 cells stimulated with LPS. Figure 11. Human PBMC from two different donors stimulated with 50 Ig/ml Poly(I:C) produce increased levels of IFN-a in the presence of Cpnl0. Figure 12. CpnlO, but not GroES, induces a dose-responsive increase in Poly(I:C)-induced IFN-P3. 30 Figure 13. CpnlO pre-incubation followed by wash reduces the Cpnl0 dose responsive increase in Poly(I:C)-induced IFN-p production. Figure 14. CpnlO does not potentiate an IFN/ response in BMM from IFNAR1-/ mice. Figure 15. Macrophage priming through the type I interferon pathway is required 35 for Cpnl 0 modulation of a TLR4 response (n = 2).

WO 2007/006095 PCT/AU2006/000980 -10 Figure 16. Serum TNFa and IFN/3 levels in mice with LPS-induced systemic inflammation. Figure 17. Survival of 6-9 day old neonate C57BL/6 mice infected with SFV. 6-9 day old neonate C57BL/6 mice were used as follows: Group A: SFV (n=13); Group B: 5 SFV + Cpnl0 20 ptg (n=13); Group C: SFV + CpnlO 50 ptg (n=13). Group B and C were injected i.p. with 20 and 50 ptg of CpnlO, followed (3 hrs later) by injection of 50 pl SFV (30 x TCID50) to all three groups. Survival is plotted according to the legend as shown. Figure 18. The Cpnl0 promoter is induced by stimulation of heat shock (HS) and stimulation of TLR. Representative assays demonstrate that heat shock with 6 hr 1o recovery significantly induced Cpnl0 promoter activity, which then returned to basal levels by 18 hr post HS (n=2 replicate assays) (A). By contrast, stimulation with LTA (TLR2 agonist) led to a 2.7-fold induction of the promoter by 24 hour stimulation and remained constant at 30 hours (A). Stimulation of cells with a titration of TLR2 (B,C), TLR7 (D,E) or TLR9 (F,G) ligands induced the Cpnl0 promoter in a dose-dependent 15is manner (n=2-6 replicates). Data presented in C, E and G reflect the same data as in B, D and F but are represented as fold change over baseline. Error bars reflect one SD of the mean. TLR agonists and cytokines induced the Cpnl0 promoter with varying maximal levels (H). Cpnl0 promoter activity is expressed as luciferase cps normalized against basal levels for each agonist. Optimal agonist concentrations and assays repeats: TLR2: 20 B. subtilis LTA 100 ptg/ml, n=12; TLR3: 100 g/ml poly(I:C), n=6; TLR4: ultrapure E. coli LPS 10 ng/ml, n=12; TLR7: imiquimod R837 10 tg/ml, n=2; TLR9, CpG ODN 1 mM, n=2; IFNy 1 ng/ml, n=3, IL-1l3 (1 ng/ml), n=2, TNF-c (100 ng/ml), n=2 (H). Significance (p<0.02) for (A) and (p<0.05) for (F) was assessed ANOVA and is indicated by *. cps = counts per second. In non-transfected RAW264.7 cells stimulated 25 with LTA, a transient concentration-dependent increase in Cpnl0 mRNA levels was measured by real-time PCR (I). Gene expression was normalized to control housekeeper genes (18S and Pbgd). Figure 19. TLR agonists and heat shock induce CpnlO production but only TLR agonists result in extracellular release of Cpnl0. Quantitative analysis of LTA-stimulated 30 RAW264.7 total cell lysates by ELISA showed little change in Cpnl0 levels between treated and control cells (A), however analysis of the culture supernatants demonstrated a 3-fold increase in extracellular Cpnl0 after 30 h 100 gg/ml LTA stimulation (B). Supernatant Cpnl0 was normalized against the number of cells per well. Time course analysis demonstrated persistent Cpnl0 promoter activation over 30 h in response to 35 TLR2 ligation. Results were standardized according to sample protein concentration (C).

WO 2007/006095 PCT/AU2006/000980 -11 Mild, moderate or severe heat shock of RAW264.7 cells did not induce the extracellular release of Cpn10 (D). Levels of Cpnl0 in the circulating blood of RA patients are significantly higher than in patients with MS or psoriasis, or healthy control subjects. Significance was analyzed by one-way ANOVA with Tukey's post-test and is indicated 5 by * (p<0.01), or ** (P<0.001) (E). Figure 20. Cpnl0 limits agonist-induced signaling through a number of TLRs. RAW264.7 cells stably transfected with the HIV-LTR-LUC promoter construct were pre incubated with Cpnl0 prior to stimulation with a variety of TLR ligands, resulting in inhibition of luciferase activity, a measure of NF-iB activation in these cells (A). Agonist o10 concentrations and time of incubation were: CpG ODN 16.25 ptg/ml, 4 h; imiquimod 10 ig/ml, 2 h; poly(I:C) 100 tg/ml, 4 h; zymosan 10 pg/ml, 2 h; PGN 10 jig/ml, 2 h; PGN 10 pg/ml, 2 h; ultrapure LPS 10 ng/ml, 2 h; LPS 5 ng/ml, 2 h. Cpn10 pre-incubation of RAW264.7 cells (B,C) or human PBMC (D) followed by LPS stimulation (10 ng/ml in RAW264.7 cells, 100 ng/ml in PBMC) leads to a dose-responsive reduction in levels of 15 phosphorylated MAPK signals. Stimulation of human PBMC with ligands to TLRs 2, 2/6, 4, 7, 9 in the presence of Cpnl0 results in decreased levels of TNF-c, IL-13, IL-6, and IL 10, and increased imiquimod- and CpG ODN-induced IFNo production (E). Concentrations of ligands used were: 10 pg/ml PGN, 10 pg/ml LTA, 10 pg/ml zymosan, 0.12 ng/ml LPS, 6.5 pg/ml CpG ODN, 10 pg/ml imiquimod 20 Figure 21. RAW264 cells grown in suspension were incubated for 4 hr in the presence of 100 tg/ml CpnlO, or the equivalent volume of diluent buffer, and then stained for the presence of TLR4. Figure 22. RAW264 cells grown in suspension were incubated for 4 hr in the presence of 100 ptg/ml Cpnl 0 or the equivalent volume of diluent buffer with or without 25 2 ng/ml LPS (added for the last 2 hr of Cpnl0 treatment) and then stained for the presence of TLR4. Figure 23. RAW264 cells grown in suspension were incubated for 4 hr in the presence of 100 ptg/ml Cpnl0 or the equivalent volume of diluent buffer, with or without 20 ng/ml LPS added for the last 2 hr Cpnl0 treatment, prior to staining for TLR4. (Mean 30 fluorescence intensity: Orange: 4.39, Black: 6.14, Blue: 25) Figure 24. RAW264 cells grown in suspension were incubated overnight in the presence of 100 ug/ml of Cpnl0 or the equivalent volume of diluent buffer, with or without LPS (2 ng/ml) added for the last 2 hr of Cpnl0 treatment, and were then stained for TLR4. Mean fluorescent intensity Blue - 25, Red - 33, Orange - 11.7, Black - 20.

WO 2007/006095 PCT/AU2006/000980 -12 Figure 25. RAW264 cells grown in suspension were incubated overnight in the presence of 100 pg/ml Cpnl10 or the equivalent volume of diluent buffer, with or without 20 ng/ml LPS added for the last 2 hr Cpnl0 treatment and then stained for TLR4. (Mean fluorescence intensity: Orange: 3.9, Black: 7.9) 5 Figure 26. Representative TLR ligands and the inhibition of luciferase activity by Cpnl0. Data in A,C,E,G, I depict luciferase units in CPS, while B,D,F, H, J represent these data as percent inhibition of luciferase activity in RAW264-HIV-LTR-LUC cells stimulated with LPS. Figure 27. Maximal Cpnl0-induced inhibition of HIV-LTR activation stimulated 10 by a broad range of TLR ligands, as an indirect measure of NF-KB activation. Figure 28. Cpnl 0 dose-responsively reduces the level of phosphorylated p38 (A), ERK1/2, and JNKl/2 (B) in cells stimulated with LPS for 30 minutes. As shown for the murine macrophage cell line RAW264.7, CpnlO dose-responsively reduced the level of LPS-induced phosphorylation of p38, ERK1/2, and JNK1/2 in freshly isolated human 15 PBMC (C). Since activation of the MAP kinase pathway is closely linked with induction of the inflammatory cascade of cytokine production, these data show that Cpnl0 mediated changes in ligand-induced cytokine production result from changes in the TLR signal cascade. Figure 29. Human PBMC stimulated with ligands to TLR2 (PGN, LTA), TLR2,6 20 (zymosan), TLR4 (LPS), TLR7 (Imiquimod), or TLR9 (CpG ODN2216) in the presence of Cpnl 0 results in decreased production of cytokines. Figure 30. CpnlO pre-incubation followed by a wash prior to LPS addition still limits NF-KB activation in a dose-responsive manner. Figure 31. CpnlO pre-incubation followed by IFN-y stimulation for 6 hours 25 results in increased TNF-c production by RAW264.7 cells. Figure 32. SDS-PAGE analysis of Cpnl0-binding molecules. SDS-PAGE gel of cell lysate proteins bound to and eluted from CpnlO affinity column. Figure 33. 2D gel electrophoresis of Cpnl0-binding molecules. 2D gel of cell lysate proteins bound to and eluted from CPn 10 affinity column. 30 Figure 34. Toxicity profile of Polyl:C in RAW264 (A) and HeLa cells (B) over 3 days. Figure 35. Influence of Cpnl0 on PolyI:C in RAW264 (A) and HeLa cells (B) over 3 days. Figure 36. Cpnl0 interacts with human antigen presenting cells at the cell 35 surface, and is internalized into endo-lysosomal compartments. Purified PBMC were WO 2007/006095 PCT/AU2006/000980 -13 incubated with fluorophore-conjugated CpnlO0 for10 min at 4oC and surface fluorescence measured by flow cytometry (A). CpnlO associated most strongly with mDC and pDC, and monocytes showed increased binding of fluorescent CpnlO following LTA stimulation over 4 h (B). RAW264.7 cells and purified human pDC were incubated with 5 fluorescent Cpnl0 for 30 min at 37 0 C prior to confocal imaging. Co-incubation with fluorescent markers of mitochondrial and acidic compartments revealed Cpn10 internalization into endo-lysosomal compartments (C). The amino acid sequence of wild-type human Cpnl0 (GenBank Accession No. X75821) is provided in SEQ ID NO:1. The amino acid sequences of two modified forms 10 of Cpnl0, with additional amino acid residues at the N-terminal are provided in SEQ ID NOs:2 and 3. The nucleotide sequence encoding the same is provided in SEQ ID NO:4. Oligonucleotide primers used in the examples as disclosed herein are provided in SEQ ID NOs: 5 - 10. 15 Best Mode of Performing the Invention CpnlO has previously been shown to reduce the production of pro-inflammatory cytokines such as TNF-cL and RANTES both in cell cultures and in vivo (see for example Johnson et al., 2005, JBiol Chem 280:4037-4047 and International Patent Application No. PCT/AU2005/000041, WO2005/067959, the disclosure of which is incorporated herein by 20 reference). These findings support the use of Cpnl0 as a therapeutic agent for the treatment of a variety of inflammatory diseases including, for example, multiple sclerosis, rheumatoid arthritis and graft-versus-host disease. Methods for modulation of Toll-like receptor signaling and immunomodulator production 25 As disclosed herein the inventors have now demonstrated that human CpnlO, when administered with the TLR3 agonist polyl:C, results in a marked synergistic increase in the production of IFNP and IFNa. Further, Cpnl 0 is demonstrated to modulate signaling via TLR7 and TLR9 as measured by reductions in NF-B activation. Moreover, the inventors have surprisingly shown that CpnlO, but not Cpn60 or 30 GroES, associates with TLR4 at the cell surface following stimulation with LPS in the form of an "activation cluster". The inventors have further shown that Cpnl0 associates with TLR2 following stimulation with liopteichoic acid (LTA), with TLR7 following stimulation with viral single-stranded RNA and/or imiquimod, and with TLR9 following stimulation with CpG DNA. In each case, such association is in the form of CpnlO 35 interacting with an "activation cluster" comprising a particular TLR and its agonist.

WO 2007/006095 PCT/AU2006/000980 -14 Accordingly, the present invention provides methods for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, wherein said methods comprise administering an effective amount of chaperonin 10, wherein Toll-like receptor signalling involves association of the chaperonin 10 with a Toll-like receptor in 5 an activation cluster. Toll-like receptor signalling may also be modulated by administering an effective amount of at least one antagonist of chaperonin 10, wherein Toll-like receptor signalling involves association of the chaperonin 10 with a Toll-like receptor in an activation cluster, and wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in 10 an activation cluster, and/or prevents signalling by the activation cluster. The activation cluster may be located on the surface of a cell or on the surface of a cellular vesicle such as an endosome. The activation cluster may comprise chaperonin 10, a Toll-like receptor, and optionally, at least one other molecule. The at least one other molecule may comprise a Toll-like receptor agonist. 15 In one embodiment, the activation cluster comprises chaperonin 10, TLR2 and lipoteichoic acid (LTA). In an additional embodiment, the activation cluster comprises chaperonin 10, TLR3 and double-stranded RNA. In another embodiment, the activation cluster comprises chaperonin 10, TLR4 and LPS. In a further embodiment, the activation cluster comprises chaperonin 10, TLR7 and single-stranded RNA. In a still further 20 embodiment, the activation cluster comprises chaperonin 10, TLR9 and DNA comprising a CpG motif The chaperonin 10 may be a naturally-derived, recombinantly produced or synthetically produced chaperonin 10. The chaperonin 10 may be of eukaryotic origin. The chaperonin 10 may be human chaperonin 10. The chaperonin 10 may comprise the 25 polypeptide sequence as set forth in SEQ ID NO:l, SEQ ID NO:2 or SEQ ID NO:3. The chaperonin 10 may be acetylated or non-acetylated, and may or may not comprise a single or multiple N-terminal extension. The chaperonin 10 may be administered in the form of a polynucleotide encoding chaperonin 10. The polynucleotide encoding chaperonin 10 may be located in a genetic construct, operably linked to a promoter. The polynucleotide may 30 comprise the sequence as set forth in SEQ ID NO:4. The method may further comprise the administration of at least one additional agent. The agent may be an immunomodulator. The immunomodulator may be, for example, TNF-L, IL-13, IL-6, IL-10, IL-12 or a type I interferon. The type I interferon may be IFNa or IFNP3.

WO 2007/006095 PCT/AU2006/000980 -15 Typically, the modulatory activity of Cpnl0 is exhibited through initial exposure of TLRs to Cpn10, and then the addition of one or more TLR agonists, as demonstrated by the inventors and disclosed herein, for example, in relation to immunomodulatory assays involving RAW264.7 cells. The agonist may be a bacterial, fungal, yeast or viral 5 pathogen, a molecule or component derived therefrom or produced thereby or a synthetic compound. The TLR agonist may also be a product from damaged human cells associated with autoimmune diseases, as exemplified by TLR9 having as an agonist human DNA. Non-limiting examples of TLR3 agonists include double-stranded RNA and polyl:C. Non-limiting examples of TLR7 agonists include single-stranded RNA, imidazoquinolines to such as resiquimod and imiquimod and small molecule agonists such as isatoribine. Non limiting examples of TLR9 agonists include DNA containing unmethylated CpG-rich motifs and synthetic CpG-comprising oligonucleotides. However those skilled in the art will readily appreciate that the present invention is not limited by the identity of the TLR agonists. s15 The present invention also provides methods for modulating the production and/or secretion of one or more immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said methods comprise administering an effective amount of chaperonin 10, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster is associated with 20 modulation of the production and/or secretion of the one or more immunomodulators. Modulation of the production and/or secretion of one or more immunomodulators may also be achieved by administering an effective amount of an antagonist of chaperonin 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein 25 formation of the activation cluster is associated with modulation of the production and/or secretion of the one or more immunomodulators. The immunomodulator may be, for example, TNF-c, IL-1 3, IL-6, IL-10, IL-12 or a type I interferon. The type I interferon may be IFNa or IFNP3. 30 Methods for treating or preventing a disease The inventors' findings as presented herein support the use of Cpnl0 in the clinical management of a variety of diseases and conditions, including acute and chronic viral and bacterial diseases. Accordingly the present invention provides methods for the treatment or prevention of viral and bacterial diseases and disorders caused by or otherwise 35 associated with viral or bacterial infections, comprising the administration of Cpnl 0.

WO 2007/006095 PCT/AU2006/000980 -16 Additionally, stimulation of TLR3, TLR7 and/or TLR9 is implicated in natural responses to and/or in therapeutic treatment of a variety of other disorders including asthma, allergy, inflammatory bowel disease and general inflammation. Thus the present invention also contemplates methods for the treatment or prevention of such diseases and 5 disorders comprising the administration of Cpnl0. Accordingly, the present invention provides methods for treating or preventing a disease or condition in a subject, wherein said methods comprise administering to the subject an effective amount of chaperonin 10, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster o10 is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition. Said methods may also comprise administering to the subject an effective amount of at least one antagonist of chaperonin 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by 15is the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or condition. The disease or condition may include, but is not limited to, the group comprising viral, fungal, yeast or bacterial infections, acute or chronic inflammatory diseases including septic shock, inflammatory bowel disease, arthritis, psoriasis, heart disease, 20 atherosclerosis, chronic pulmonary disease, cachexia, multiple sclerosis, GVHD and cancer. Any disease or condition, the establishment and/or progression of which, or the initiation, enhancement and/or maintenance of an immune response against which, involves the association of chaperonin 10 with a Toll-like receptor in an activation cluster, is contemplated as within the scope of the present invention. 25 In one embodiment, the chaperonin 10 regulates LTA-induced TLR2 signalling. The chaperonin 10 may modulate TLR2-induced immunomodulator production and/or secretion. In an additional embodiment, the chaperonin 10 regulates double-stranded RNA-induced TLR3 signalling. The chaperonin 10 may modulate TLR3-induced immunomodulator production and/or secretion. In another embodiment, the chaperonin 10 30 regulates LPS-induced TLR4 signalling. The chaperonin 10 may modulate TLR4-induced immunomodulator production and/or secretion. In a further embodiment, the chaperonin 10 regulates viral single-stranded RNA-induced TLR7 signalling. The chaperonin 10 may modulate TLR7-induced immunomodulator production and/or secretion. In a still further embodiment, the chaperonin 10 regulates CpG motif-induced TLR9 signalling. The WO 2007/006095 PCT/AU2006/000980 -17 chaperonin 10 may modulate TLR9-induced immunomodulator production and/or secretion. Compositions and uses thereof 5 The present invention provides compositions when used for the treatment or prevention of a disease or condition, the compositions comprising chaperonin 10 together with at least one pharmaceutically acceptable carrier, diluent or adjuvant, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster is associated with initiation, enhancement and/or 10 maintenance of an immune response to the disease or condition. The compositions may further comprise at least one agonist of a Toll-like receptor. The composition may further comprise at least one immunomodulator such as a type I interferon. Other compositions used for the treatment or prevention of a disease or condition, 15 the composition comprise at least one antagonist of chaperonin 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or condition. 20 Uses of chaperonin 10 for the manufacture of a medicament for the treatment or prevention of a disease or condition are also contemplated, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition. 25 Uses of antagonists of chaperonin 10 for the manufacture of a medicanment for the treatment or prevention of a disease or condition are also contemplated, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or 30 condition. In general, suitable compositions for use in accordance with the methods of the present invention may be prepared according to methods and procedures that are known to those of ordinary skill in the art and accordingly may include a pharmaceutically acceptable carrier, diluent and/or adjuvant. 35 WO 2007/006095 PCT/AU2006/000980 -18 Combination therapies Those skilled in the art will appreciate that in accordance with the methods of the present invention CpnlO may be administered alone or in conjunction with one or more additional agents. For example, Cpnl0 may be administered together with one or more 5 TLR agonists capable of stimulating one or more of TLR2, TLR3, TLR4, TLR7 and TLR9. Additionally, the present invention contemplates combination therapy using Cpnl0 in conjunction with other therapeutic approaches to the treatment of diseases and disorders. For example, CpnlO may be useful in the treatment of viral diseases which are responsive to therapy with Type I interferons such as IFN3 or IFNcX. Further, as agonist 10 induced activation of TLR7 and TLR9 has previously been reported to enhance the response of tumours to radiation therapy, CpnlO may be used in conjunction with radiation therapy for the treatment of cancer. For such combination therapies, each component of the combination therapy may be administered at the same time, or sequentially in any order, or at different times, so as 15 to provide the desired effect. Alternatively, the components may be formulated together in a single dosage unit as a combination product. When administered separately, it may be preferred for the components to be administered by the same route of administration, although it is not necessary for this to be so. 20 Cpnl0 In accordance with aspects and embodiments of the present invention, a subject in need of treatment is administered with an effective amount of Cpnl0. In particular embodiments the subject to be treated is a human, and accordingly, the Cpnl0 polypeptide is the human Cpnl0 polypeptide. Those skilled in the art will appreciate that the precise 25 identity of the Cpnl0 used in accordance with the present invention may vary depending on a number of factors, for example the species to be treated, such that the Cpnl0 may be selected so as to be derived from the species to be treated. Typically, the Cpnl0 is recombinant Cpnl0. Methods described in Morton et al., 2000 (Immunol Cell Biol 78:603-607), Ryan et al., 1995 (JBiol Chem 270:22037-22043) 30 and Johnson et al., 2005 (J Biol Chem 280:4037-4047) are examples of suitable production methods for recombinant Cpnl0 protein, although the skilled addressee will appreciate that the present invention is not limited by the method of purification or production used and any other method may be used to produce Cpn0O for use in accordance with the methods and compositions of the present invention.

WO 2007/006095 PCT/AU2006/000980 - 19 Cpnl0 polypeptides and peptide fragments for use in accordance with the present invention may be obtained using of standard recombinant nucleic acid techniques or may be synthesized, for example using conventional liquid or solid phase synthesis techniques. Cpnl0 peptides may be produced by digestion of a polypeptide with one or more 5 proteinases such as endoLys-C, endoArg-C, endoGlu-C and staphylococcus V8-protease. The digested peptide fragments can be purified by, for example, high performance liquid chromatographic (HPLC) techniques. Embodiments of the invention also contemplate the administration of a polynucleotide encoding Cpnl0. In such situations the polynucleotide is typically 10 operably linked to a promoter such that the appropriate polypeptide sequence is produced following administration of the polynucleotide to the subject. The polynucleotide may be administered to subjects in a vector. The vector may be a plasmid vector, a viral vector, or any other suitable vehicle adapted for the insertion of foreign sequences, their introduction into eukaryotic cells and the expression of the introduced sequences. Typically the vector 15is is a eukaryotic expression vector and may include expression control and processing sequences such as a promoter, an enhancer, ribosome binding sites, polyadenylation signals and transcription termination sequences. The nucleic acid construct to be administered may comprise naked DNA or may be in the form of a composition, together with one or more pharmaceutically acceptable carriers. 20 The Cpnl10 polypeptide may have, but is not limited to, the amino acid sequence as set forth in SEQ ID NO: 1. The nucleotide sequence of the polynucleotide encoding Cpnl0 may be as set forth in SEQ ID NO:4 or display sufficient sequence identity thereto to hybridise to the sequence of SEQ ID NO:4. In alternative embodiments, the nucleotide sequence of the polynucleotide may share at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 25 90%, 96%, 97%, 98% or 99% identity with the sequence set forth in SEQ ID NO:4. Within the scope of the terms "polypeptide" and "polynucleotide" as used herein are fragments and variants thereof. By way of example only, peptide fragments of CpnlO as described in WO 95/15338 may be used in accordance with aspects and embodiments of the present invention. 30 The term "fragment" refers to a nucleic acid or polypeptide sequence that encodes a constituent or is a constituent of full-length Cpnl0 protein. In terms of the polypeptide the fragment possesses qualitative biological activity in common with the full-length protein. A biologically active fragment of Cpnl0 used in accordance with the present invention may typically possess at least about 50% of the immunomodulatory activity of 3s the corresponding full length protein, more typically at least about 60% of such activity, WO 2007/006095 PCT/AU2006/000980 - 20 more typically at least about 70% of such activity, more typically at least about 80% of such activity, more typically at least about 90% of such activity, and more typically at least about 95% of such activity. The term "variant" as used herein refers to substantially similar molecules. 5 Generally, nucleic acid sequence variants encode polypeptides which possess qualitative biological activity in common. Generally, polypeptide sequence variants also possess qualitative biological activity in common. Further, these polypeptide sequence variants may share at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity. 0 Further, a variant polypeptide may include analogues, wherein the term "analogue" means a polypeptide which is a derivative of Cpnl0, which derivative comprises addition, deletion, substitution of one or more amino acids, such that the polypeptide retains substantially the same function as native Cpnl0. It is well known in the art that some amino acids may be changed within a polypeptide without altering the activity of the 15is polypeptide (conservative substitutions). The term "conservative amino acid substitution" refers to a substitution or replacement of one amino acid for another amino acid with similar properties within a polypeptide chain (primary sequence of a protein). For example, the substitution of the charged amino acid glutamic acid (Glu) for the similarly charged amino acid aspartic acid (Asp) would be a conservative amino acid substitution. 20 Amino acid additions may result from the fusion of a Cpnl0 polypeptide or fragment thereof with a second polypeptide or peptide, such as a polyhistidine tag, maltose binding protein fusion, glutathione S transferase fusion, green fluorescent protein fusion, or the addition of an epitope tag such as FLAG or c-myc. For example, the wild-type human Cpnl0 polypeptide may comprise an additional GSM tripeptide moiety at the N-terminus 25 (SEQ ID NO:2; see for example WO 95/15338, the disclosure of which is incorporated herein by reference) or an additional alanine (A) reside at the N-terminus (SEQ ID NO:3; WO 2004/041300, the disclosure of which is incorporated herein by reference). Other mutated forms of Cpnl0 include those disclosed in Australian provisional patent application No. 2005904765, the disclosure of which is incorporated herein by reference. 30 The present invention also contemplates the use of polynucleotides encoding such modified forms of Cpn10. CpnlO variants can be generated by mutagenesis of a Cpnl0 protein or mutagenesis of an encoding nucleic acid, such as by random mutagenesis or site-directed mutagenesis using methods well known to those skilled in the art. Such methods may be 35 found, for example in Current Protocols In Molecular Biology (Chapter 9), Ausubel et al., WO 2007/006095 PCT/AU2006/000980 -21 1994, John Wiley & Sons, Inc., New York, the disclosure of which is incorporated herein by reference. Variants and analogues also encompass polypeptides complexed with other chemical moieties, fusion proteins or otherwise post-transitionally modified. Examples of suitable modifications are described in co-pending International Patent Application No. 5 PCT/AU2005/000041; WO2005/067959, the disclosure of which is incorporated herein by reference. Further, the Cpnl0 polypeptide or fragment thereof may possess other post translational modifications, including side-chain modifications such as for example acetylation, amidination, carbamoylation, reductive alkylation and other modifications as to are known to those skilled in the art. A Cpnl0 polynucleotide may further comprise, but is not limited to, any polynucleotide that hybridizes to a Cpnl0 polynucleotide as defined herein under conditions of high stringency. The term "high stringency" as used herein refers to the conditions under which two polynucleotides may be hybridized, and may include, for 5is example, the concentration of salts and/or detergents in a solution, the temperature of a solution that is used during the hybridization of the two polynucleotides and time period of the hybridization. Accordingly, the term "high stringency" as used herein refers to conditions in a solution that are conducive to hybridization of two polynucleotides only where such polynucleotides share a high degree of homology. The degree of homology 20 may include, but not be limited to, a range of from about 50% to 99%. Thus, "high stringency" conditions may involve, but are not limited to, the use of a wash buffer that comprises 0 to 10% sodium dodecyl sulfate and/or 0 to lx sodium chloride-sodium citrate at a temperature in the range of from about 60 0 C to 70 0 C, or any other combination of buffers, temperature or time period which would yield a "high 25 stringency" solution for hybridization. Routes of administration Compositions may be administered by standard routes. In general, the compositions may be administered by the parenteral (e.g., intravenous, intraspinal, 30 subcutaneous or intramuscular), oral or topical route. Administration may be systemic, regional or local. The particular route of administration to be used in any given circumstance will depend on a number of factors, including the nature of the condition to be treated, the severity and extent of the condition, the required dosage of the particular compound to be delivered and the potential side-effects of the compound.

WO 2007/006095 PCT/AU2006/000980 - 22 The compositions of the invention may be in a form suitable for administration by injection, in the form of a formulation suitable for oral ingestion (such as capsules, tablets, caplets, elixirs, for example), in the form of an ointment, cream or lotion suitable for topical administration, in a form suitable for delivery as an eye drop, in an aerosol form 5 suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation, in a form suitable for parenteral administration, that is, subcutaneous, intramuscular or intravenous injection. For administration as an injectable solution or suspension, non-toxic parenterally acceptable diluents or carriers can include, Ringer's solution, isotonic saline, phosphate 10 buffered saline, ethanol and 1,2 propylene glycol. Diluents, carriers, adjuvants and excipients In general, suitable compositions may be prepared according to methods which are known to those of ordinary skill in the art and may include a pharmaceutically acceptable 15 diluent, adjuvant and/or excipient. The diluents, adjuvants and excipients must be "acceptable" in terms of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof. Examples of pharmaceutically acceptable carriers or diluents include, but are not limited to, demineralised or distilled water, saline solution, vegetable based oils such as 20 peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or 25 hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3 butylene glycol or glycerin; fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate; polyvinylpyrridone; agar; carrageenan; gum tragacanth or gum 30 acacia, and petroleum jelly. Typically, the carrier or carriers will form from 10% to 99.9% by weight of the compositions. Some examples of suitable carriers, diluents, excipients and adjuvants for oral use include, but are not limited to, peanut oil, liquid paraffin, sodium carboxymethylcellulose, methylcellulose, sodium alginate, gum acacia, gum tragacanth, dextrose, sucrose, sorbitol, 35 mannitol, gelatine and lecithin. In addition these oral formulations may contain suitable WO 2007/006095 PCT/AU2006/000980 - 23 flavouring and colourings agents. When used in capsule form the capsules may be coated with compounds such as glyceryl monostearate or glyceryl distearate which delay disintegration. Adjuvants typically include, but are not limited to, emollients, emulsifiers, 5 thickening agents, preservatives, bactericides and buffering agents. Solid forms for oral administration may contain, but are not limited to, binders acceptable in human and veterinary pharmaceutical practice, sweeteners, disintegrating agents, diluents, flavourings, coating agents, preservatives, lubricants and/or time delay agents. Suitable binders include, but are not limited to, gum acacia, gelatine, corn starch, 10 gum tragacanth, sodium alginate, carboxymethylcellulose or polyethylene glycol. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine. Suitable disintegrating agents include, but are not limited to, corn starch, methylcellulose, polyvinylpyrrolidone, guar gum, xanthan gum, bentonite, alginic acid or agar. Suitable diluents include, but are not limited to, lactose, sorbitol, mannitol, dextrose, kaolin, 15is cellulose, calcium carbonate, calcium silicate or dicalcium phosphate. Suitable flavouring agents include, but are not limited to, peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring. Suitable coating agents include, but are not limited to, polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include, but are not limited to, 20 sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include, but are not limited to, magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate. Liquid forms for oral administration may contain, in addition to the above agents, a 25 liquid carrier. Suitable liquid carriers include, but are not limited to, water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof. Suspensions for oral administration may further comprise dispersing agents and/or 30 suspending agents. Suitable suspending agents include, but are not limited to, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, poly-vinyl pyrrolidone, sodium alginate or acetyl alcohol. Suitable dispersing agents include, but are not limited to, lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitol mono- or di-oleate, -stearate or -laurate, polyoxyethylene 35 sorbitan mono- or di-oleate, -stearate or -laurate and the like.

WO 2007/006095 PCT/AU2006/000980 - 24 The emulsions for oral administration may further comprise one or more emulsifying agents. Suitable emulsifying agents include, but are not limited to, dispersing agents as exemplified above or natural gums such as guar gum, gum acacia or gum tragacanth. 5 Methods for preparing parenterally administrable compositions are apparent to those skilled in the art, and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa., hereby incorporated by reference herein. The topical formulations of the present invention, comprise an active ingredient 10 together with one or more acceptable carriers, and optionally any other therapeutic ingredients. Formulations suitable for topical administration include, but are not limited to, liquid or semi-liquid preparations suitable for penetration through the skin to the site of where treatment is required, such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. 15 Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions. These may be prepared by dissolving the active ingredient in an aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container and sterilised. 20 Sterilisation may be achieved by: autoclaving or maintaining at 90 0 C-100oC for half an hour, or by filtration, followed by transfer to a container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution 25 include, but are not limited to, glycerol, diluted alcohol and propylene glycol. Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those described above in relation to the preparation of drops. Lotions or liniments for application to the skin may 30 also include, but are not limited to, an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturiser such as glycerol, or oil such as castor oil or arachis oil. Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by 35 mixing the active ingredient in finely-divided or powdered form, alone or in solution or WO 2007/006095 PCT/AU2006/000980 - 25 suspension in an aqueous or non-aqueous fluid, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together 5 with an alcohol such as propylene glycol or macrogols. The composition may incorporate any suitable surfactant such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be to included. The compositions may also be administered in the form of liposomes. Liposomes are generally derived from phospholipids or other lipid substances, and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming 15 liposomes can be used. The compositions in liposome form may contain stabilisers, preservatives, excipients and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art, and in relation to this specific reference is made to: Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et 20 seq., the contents of which is incorporated herein by reference. The compositions may be conjugated to an array of polyethylene glycol (PEG) derivatives. The addition of PEG to proteins (PEGylation) is a well established method for decreasing the plasma clearance rates of proteins, thereby increasing their efficacy (Nucci et al., 1991, Adv. Drug Del. Rev. 6:133). Additional benefits of PEGylation may 25 include, greater stability of proteins, decreased immunogenicity, enhanced solubility and decreased susceptibility to proteolysis (Sheffield W. 2001, Curr Drug Targets Cardiovasc Haemnatol Disord. 1:1-22). PEG molecules contain the basic repeating structure of-(OCH 3

CH

2 )n-OH and are classified into groups according to their molecular weight. PEG derivatives are conjugated to proteins to increase their hydrodynamic radius 30 and in general, their increase in half-life is directly related to the size of the PEG chain attached (Sheffield W. 2001, Curr Drug Targets Cardiovasc Haemnatol Disord. 1:1-22). The compositions may also be administered in the form of microparticles. Biodegradable microparticles formed from polylactide (PLA), polylactide-co-glycolide (PLGA), and epsilon-caprolactone (t-caprolactone) have been extensively used as drug 35 carriers to increase plasma half life and thereby prolong efficacy (R. Kumar, M., 2000, J WO 2007/006095 PCT/AU2006/000980 - 26 Pharm Pharmaceut Sci. 3(2) 234-258). Microparticles have been formulated for the delivery of a range of drug candidates including vaccines, antibiotics, and DNA. Moreover, these formulations have been developed for various delivery routes including parenteral subcutaneous injection, intravenous injection and inhalation. 5 The compositions may incorporate a controlled release matrix that is composed of sucrose acetate isobutyrate (SAIB) and organic solvent or organic solvents mixture. Polymer additives may be added to the vehicle as a release modifier to further increase the viscosity and slow down the release rate. SAIB is a well known food additive. It is a very hydrophobic, fully esterified sucrose derivative, at a nominal ratio of six isobutyrate io to two acetate groups. As a mixed ester, SAIB does not crystallize but exists as a clear viscous liquid. Mixing SAIB with a pharmnnaceutically accepted organic solvent such as ethanol or benzyl alcohol decreases the viscosity of the mixture sufficiently to allow for injection. An active pharmaceutical ingredient may be added to the SAIB delivery vehicle to form SAIB solution or suspension formulations. When the formulation is 15is injected subcutaneously, the solvent diffuses from the matrix allowing the SAIB-drug or SAIB-drug-polymer mixtures to set up as an in situ forming depot. For the purposes of the present invention molecules and agents may be administered to subjects as compositions either therapeutically or preventively. In a therapeutic application, compositions are administered to a patient already suffering from 20 a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. The composition should provide a quantity of the molecule or agent sufficient to effectively treat the patient. Dosages 25 The therapeutically effective dose level for any particular patient will depend upon a variety of factors including: the disorder being treated and the severity of the disorder; activity of the molecule or agent employed; the composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of sequestration of the molecule or agent; the duration of the 30 treatment; drugs used in combination or coincidental with the treatment, together with other related factors well known in medicine. One skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic amount of agent or compound which would be required to treat applicable diseases.

WO 2007/006095 PCT/AU2006/000980 - 27 Generally, an effective dosage is expected to be in the range of about 0.0001mg to about 1000mg per kg body weight per 24 hours; typically, about 0.001mg to about 750mg per kg body weight per 24 hours; about 0.01mg to about 500mg per kg body weight per 24 hours; about 0.1mg to about 500mg per kg body weight per 24 hours; about 0.1mg to 5 about 250mg per kg body weight per 24 hours; about 1.0mg to about 250mg per kg body weight per 24 hours. More typically, an effective dose range is expected to be in the range about 1.0mg to about 200mg per kg body weight per 24 hours; about 1.0mg to about 100mg per kg body weight per 24 hours; about 1.0mg to about 50mg per kg body weight per 24 hours; about 1.0mg to about 25mg per kg body weight per 24 hours; about 5.0mg o10 to about 50mg per kg body weight per 24 hours; about 5.0mg to about 20mg per kg body weight per 24 hours; about 5.0mg to about 15mg per kg body weight per 24 hours. Alternatively, an effective dosage may be up to about 500mg/m 2 . Generally, an effective dosage is expected to be in the range of about 25 to about 500mg/m 2 , preferably about 25 to about 350mg/m 2 , more preferably about 25 to about 300mg/m 2 , still more 15is preferably about 25 to about 250mg/m 2 , even more preferably about 50 to about 250mg/m 2 , and still even more preferably about 75 to about 150mg/m 2. Typically, in therapeutic applications, the treatment would be for the duration of the disease state. Further, it will be apparent to one of ordinary skill in the art that the optimal 20 quantity and spacing of individual dosages will be determined by the nature and extent of the disease state being treated, the form, route and site of administration, and the nature of the particular individual being treated. Also, such optimum conditions can be determined by conventional techniques. It will also be apparent to one of ordinary skill in the art that the optimal course of 25 treatment, such as, the number of doses of the composition given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. CpnlO agonists and antagonists 30 The present invention also contemplates the use of agonists and antagonists of Cpnl 0 and methods of screening and producing such agonists and antagonists. Cpnl0 agonists and antagonists may be specifically designed or screened according to their effect upon Toll-like receptor signalling and immunomodulator secretion.

WO 2007/006095 PCT/AU2006/000980 - 28 Antibodies may act as agonists or antagonists of Cpnl0, or fragments or analogues thereof Preferably suitable antibodies are prepared from discrete regions or fragments of the Cpnl0 polypeptide, in particular those involved in conferring protease activity and/or partner or substrate binding. An antigenic Cpn10 polypeptide contains at least about 5, 5 and preferably at least about 10, amino acids. Methods for the generation of suitable antibodies will be readily appreciated by those skilled in the art. For example, an anti-CpnlO monoclonal antibody, typically containing Fab portions, may be prepared using the hybridoma technology described in Antibodies-A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor 10 Laboratory, N.Y. (1988). In essence, in the preparation of monoclonal antibodies directed toward Cpnl0, or fragment or analogue thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include the hybridoma technique originally developed by Kohler et al., 1975, Nature, 256:495-497, as well as the is trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Innunology Today, 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., in Monoclonal Antibodies and Cancer Therapy, pp. 77-96, Alan R. Liss, Inc., (1985)). Immortal, antibody-producing cell lines can be created by techniques other than fusion, such as direct transformation of B lymphocytes with 20 oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., "Hybridoma Techniques" (1980); Hammerling et al., "Monoclonal Antibodies and T-cell Hybridomas" (1981); Kennett et al., "Monoclonal Antibodies" (1980). In summary, a means of producing a hybridoma from which the monoclonal antibody is produced, a myeloma or other self-perpetuating cell line is fused with 25 lymphocytes obtained from the spleen of a mammal hyperimmunised with a recognition factor-binding portion thereof, or recognition factor, or an origin-specific DNA-binding portion thereof. Hybridomas producing a monoclonal antibody useful in practicing this invention are identified by their ability to immunoreact with the present recognition factor and their ability to inhibit specified transcriptional activity in target cells. 30 A monoclonal antibody useful in practicing the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate antigen specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody- WO 2007/006095 PCT/AU2006/000980 - 29 containing medium is then collected. The antibody molecules can then be further isolated by well-known techniques. Similarly, there are various procedures known in the art which may be used for the production of polyclonal antibodies. For the production of anti-CpnlO polyclonal 5 antibody, various host animals can be immunized by injection with Cpnl0, or a fragment or analogue thereof, including but not limited to horses, cows, rabbits, chickens, mice, rats, sheep, goats, etc. Further, the Cpnl0 polypeptide or fragment or analogue thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Also, various adjuvants may be used to increase the 10 immunological response, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminium hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette Guerin) and Corynebacterium parvum. 15 Screening for the desired antibody can also be accomplished by a variety of techniques known in the art. Assays for immunospecific binding of antibodies may include, but are not limited to, radioimmunoassays, ELISAs (enzyme-linked immunosorbent assay), sandwich immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays, Western blots, 20 precipitation reactions, agglutination assays, complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, and the like (see, for example, Ausubel et al., eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York). Antibody binding may be detected by virtue of a detectable label on the primary antibody. Alternatively, the antibody may be detected 25 by virtue of its binding with a secondary antibody or reagent which is appropriately labelled. A variety of methods are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. The antibody (or fragment thereof) raised against CpnlO or a fragment or analogue thereof has binding affinity for Cpnl 0. Preferably, the antibody (or fragment thereof) has 30 binding affinity or avidity greater than about 105 M -1 , more preferably greater than about 106 M

-

, more preferably still greater than about 107 M- and most preferably greater than about 108 M -1. haIn terms of obtaining a suitable amount of an antibody according to the present invention, one may manufacture the antibody(s) using batch fermentation with serum free 35 medium. After fermentation the antibody may be purified via a multistep procedure WO 2007/006095 PCT/AU2006/000980 - 30 incorporating chromatography and viral inactivation/removal steps. For instance, the antibody may be first separated by Protein A affinity chromatography and then treated with solvent/detergent to inactivate any lipid enveloped viruses. Further purification, typically by anion and cation exchange chromatography may be used to remove residual 5 proteins, solvents/detergents and nucleic acids. The purified antibody may be further purified and formulated into 0.9% saline using gel filtration columns. The formulated bulk preparation may then be sterilised and viral filtered and dispensed. Agonists and antagonists other than antibodies are also contemplated. A candidate agonist or antagonist may be identified by an ability to form a molecular complex with a o10 Toll-like receptor, and optionally a Toll-like receptor agonist. Further, a candidate antagonist may be identified by an ability to prevent or disrupt formation of a molecular complex comprising Cpnl0, and a Toll-like receptor or a Toll-like receptor agonist. Techniques and procedures for identifying and producing agonists and antagonists are well known to those skilled in the art, including screening of libraries of molecules 15is such as synthetic chemical libraries such as combinatorial libraries, computer assisted screening of structural databases, computer-assisted modelling and/or design, or more traditional biophysical techniques which detect molecular binding interactions. The present invention will now be further described in greater detail by reference to the following specific examples, which should not be construed as in any way limiting the 20 scope of the invention. Examples Recombinant human Cpnl O For the experiments described in Examples 1 to 4 below, recombinant human 25 CpnlO (GenBank Accession No. X75821) was produced in E. coli with an N-terminal Alanine residue as described in Johnson et al., 2005 (JBiol Chem 280:4037-4047). Purity was determined to be >97% by SDS-PAGE. Frozen aliquots of CpnlO were thawed only once prior to use. All CpnlO batches showed the same molar activity as E. coli GroES in GroEL-mediated rhodanese refolding assays (data not shown). 30 Example 1- Production of the antiviral cytokine IFNP3 in the presence of polyl:C Experiments were carried out to determine the effect of Cpnl0 on the production of the antiviral cytokine interferon-P (IFNI3), when administered in combination with the selective agonist of TLR3, polyl:C (polyinosinic-polysytidilic acid).

WO 2007/006095 PCT/AU2006/000980 -31 Experiments were conducted in the murine macrophage cell line RAW264.7 (ATCC Accession No TIB71) as described in Johnson et al., 2005 (J Biol Chem 280:4037-4047). Briefly, RAW264.7 cells were seeded at 2 x 105 cells/well in 24 well plates and cultured overnight (37 0 C, 5% CO 2 ). Recombinant human CpnlO (at 5 concentrations between 10 pLg/ml and 200 pg/ml) or buffer was added to cells in duplicate for 2 hours followed by the addition of polyl:C (tlrl-pic, InvivoGen, San Diego, CA) to a final concentration of 100 pLg/ml. After 24 hours, supernatants were collected and analysed for IFNP3 levels using a specific ELISA according to manufacturer's instructions (Cat No. 42400-1, R&D Systems Inc, Minneapolis, MN). 10 As shown in Figure 1, unstimulated RAW264.7 cells released no detectable IFNP into the culture supernatant. Stimulation with polyl:C at 100 tg/ml resulted in 292 pg/ml of IFNP3 being released into the RAW264.7 culture supernatants in the absence of Cpnl0. Addition of increasing doses of Cpnl 0 from 10 pLg/ml up to 200 jig/ml resulted in a dose dependent increase in levels of IFNP3 in the culture supernatants, reaching a maximum 15is level of 900 pg/ml IFNP3 at 150 jtg/ml Cpnl0. Example 2- Anti-viral activity of RAW264.7 cell supernatants The cell culture supernatants obtained from the experiments described in Example 1 above were frozen and stored at -20 0 C prior to analysis for total anti-viral activity (total 20 type I interferon release) in an L cell cytopathic effect reduction (CPER) assay. Briefly, 3 x 104 L cells were seeded into 96-well plates and left for 4 h at 37oC to adhere. Duplicates of IFN standards and test supernatants were added to the plate in semi logl 0 serial dilutions. The dilutions of standards were such to give a range of IFN activity from 1 to 10 4 IU/ml. The plate was incubated overnight for 15 h, the medium was 25 removed, and Semliki Forest virus was added to the wells at a titer 100 times that of the tissue culture ID 50 . Plates were incubated for 3 days at 37 0 C and then scored for cell viability. Every plate contained a duplicate row of cells without either IFN or test supernatant to serve as a control for maximal cell death. IFN titers were determined as the concentration of IFN to provide protection to 50% of the cells relative to National 30 Institutes of Health standard Ga02901511. As illustrated in Figure 2, the addition of Cpn 10 resulted in a significant dose-responsive increase in the release of type I interferons (to a maximum at 100 pg/ml Cpnl0) in the presence of polyl:C. The data presented in Examples 1 and 2 indicate that administration of CpnlO in the context of a viral infection where viral nucleic acids may be released, or when co- WO 2007/006095 PCT/AU2006/000980 - 32 administered with a TLR3 agonist result in the stimulation of an enhanced level of anti viral immunity. Example 3- NF-rB activation in HEK293 cells expressing TLR7 s The ability of human Cpnl0 to modulate signalling via the Toll-like receptor TLR7 was investigated in the human embryonic kidney cell line HEK293. Stable cell lines of HEK293 expressing both TLR7 and TLR4 were established as described in Latz et al., 2002 (JBiol Chemn 277:47834-47843) and seeded into 96-well plates at a density of 2 x 10 4 cells per well. Following overnight growth, to enable determination of NF-cB 10 activation, cells were transiently transfected with an NF-icB-luciferase reporter construct (as per Latz et al., 2002, J Biol Chem 277:47834-47843), comprising an artificial promoter composed of a multimer of 5 NF-KB sites driving expression of the firefly luciferase gene, together with the constitutively active Renilla luciferase reporter gene. Following culture of the cells overnight, recombinant human Cpn10 was 15 administered to the cells at a final concentration of 50 [g/ml either alone or simultaneously with one of the following: the TLR7 selective agonist Resiquimod R848, a phosphothioate CpG oligonucleotide (MWG Biotech) (TLR9 selective agonist), the TLR4 selective agonist lipopolysaccharide (LPS) or the protein kinase C activator phorbol 12 myristate 13-acetate (PMA), by way of a control. 20 NF-icB activation was then determined and quantified 5 h post-stimulation by measurement of luciferase activity using the Dual-Luciferase Assay Reporter System according to manufacturer's instructions (Promega, Madison WI) and a plate reader luminometer (Perkin Elmer). The results, expressed as fold NF-Bd3 activation are shown in Figure 3. In the 25 absence of stimulation (medium alone) NF-cB activation was not induced. In contrast, the TLR7 selective agonist R848 at concentrations ranging from 0.32 - 40 gM induced more than 5-fold activation of NF-rB via TLR7. However in the presence of 50 pg/ml Cpn 10, this activation was reduced by approximately 2-fold. 30 Example 4- NF-KB activation in HEK293 cells expressing TLR9 The ability of human Cpnl0 to modulate signalling via the Toll-like receptor TLR9 was also investigated in HEK293 cells. Assays were performed as described in Example 3.

WO 2007/006095 PCT/AU2006/000980 - 33 Assays were conducted on two independent clones of stably transfected HEK293 cells expressing TLR9. Results are shown in Figure 4. In the absence of stimulation (medium alone) NF-YB activation was not induced. However activation of HEK-TLR9 with CpG DNA at concentrations ranging from 0.08 - 10 gM induced up to approximately 5 33-fold activation of NF-kB. This was reduced in the presence of 50 Rg/ml Cpnl0 by 5 to 10-fold. To further investigate the effect of Cpnl0 on responsiveness of HEK293 cells expressing TLR9 to CpG DNA, similar experiments to those described above were performed using varying concentrations of CpnlO- 12.5 tg/ml, 25 tg/ml, 50 gg/ml and 10 100 pg/ml (see Figure 5). These results confirm the Cpnl0-mediated effect observed above (Figure 4) and illustrate the dose-responsiveness of the Cpnl0-mediated effect on TLR9 signalling. Example 5- Cytokine release from human peripheral blood mononuclear cells 15 To determine the ability of CpnlO to modulate cytokine release in primary human cells, human peripheral blood mononuclear cells (PBMCs) isolated from healthy volunteer donors were used. PBMCs were isolated from heparinized blood by buoyant density gradient centrifugation as described in Johnson et al., 2005 (JBiol Chemn 280:4037-4047). One half of the isolated PBMCs were treated to remove plasmacytoid dendritic 20 cells (PDCs) from the cell population using anti-BDCS-2-APC columns (Miltenyi) as described in Latz et al., 2004 (Nature Immunol 5:190-198). PDCs are the primary source of the type I interferon IFNa within the PBMC population. PDCs are known to express TLR7 and TLR9 and are the critical cell type in humans for recognition of single stranded nucleic acids. 25 For both PBMC containing PDCs and PBMC depleted of PDCs, cells were seeded into 96-well plates at 106 viable cells per ml in 200 pl and cultured as described in Johnson et al., 2005 (JBiol Chem 280:4037-4047). Briefly, Cpnl0 was added to a final concentration of 1 pg/ml, 10 pg/ml or 50 pg/ml and plates incubated for 1 hour before LPS (non-repurified or repurified) was added. Cells were then incubated for a further 20 30 hours at 37 0 C and 5% CO 2 . Supernatants were collected and analysed for production of the pro-inflammatory cytokine TNF-a (Figure 6) and the anti-inflammatory cytokine IL 10 (Figure 7) using specific ELISAs according to manufacturer's instructions (R&D Systems, Inc., Minneapolis, MN). As shown in Figures 6 and 7, neither medium alone nor Cpnl0 induced production 35 of TNF-a or IL-10 in the absence of LPS.

WO 2007/006095 PCT/AU2006/000980 - 34 The addition of re-purified LPS (from 0.01 - 10 ng/ml) to intact PBMC cultures resulted in production of TNF-a that was dose-responsively decreased (maximum 32%) in the presence of up to 10 pg/ml Cpnl0 (Figure 6A). However in PBMC depleted of PDCs, the influence of CpnlO on TNF-a production was lost (Figure 6B). Thus the effect of 5 CpnlO on the LPS-induced production of TNF-a requires the presence of PDCs and is cancelled in their absence. This finding is somewhat surprising as PDCs do not express TLR4 and thus do not respond to stimulation with LPS, thus suggesting that the modulatory effect of Cpnl 0 on TLR4 directed signaling may be indirect. In the case of IL-10 (Figure 7), supernates from PBMC demonstrated increase in 10 IL-10 production in the presence of Cpnl0, although supernates from PBMC depleted of PDCs demonstrated a greater dose-responsive (up to 10 ig/ml Cpnl0) increase in IL-10 production (Figure 7B) than observed in intact PBMC with PDCs (Figure 7A). Example 6- Cpn10 modulation of TLR3 activation 15is This study was undertaken to determine whether Cpnl0 differentially regulates the response to ligation of TLR3 verses other TLRs, which may indicate a target of molecular interaction. Stimulation of TLRs by specific agonists triggers the activation of two downstream signaling pathways, either MyD88-dependent or -independent. MyD88 is an 20 adaptor molecule common to all TLRs, except for TLR3. The function of this molecule is to recruit IL-1R-associated kinase (IRAK) and TNFR-associated factor 6 (TRAF6) together to activate IKB (IKK)capy3 kinase complex, which then phosphorylates IdBc, leading to nuclear translocation and DNA binding of NF-r3. MyD88-independent activation of TLRs involves activation of Toll/IL-1R domain-containing adaptor 25 inducing IFN-P3 (TRIF). This results in delayed activation of NF-KB, and IFN regulatory factor 3 (IRF3) which leads to the production of IFN-P and expression of IFN-inducible genes. Ligation of TLR3 primarily activates the TRIF pathway, whereas TLR4 activates both MyD88- and TRIF-dependent pathways. One of the aims of this study was to determine whether Cpnl0 could regulate the dynamics of the response due to activation 30 of TLR3 verses other TLRs, and thereby provide some information on the target and mode of action of Cpnl0. 6.1 General Materials CpnlO batch CHOO3 and GroES were used with and without LPS (Sigma) and 35 Poly(I:C) (Invivogen). Cell lines used included RAW264-pNifty2-LUC and RAW264.7.

WO 2007/006095 PCT/AU2006/000980 - 35 6.2 Results 6.2.1 Cpnl0 does not inhibit NF-icB activation through TLR3 5 The mouse macrophage-like cell line RAW264.7 was stably transfected with a plasmid driven by the ELAM1 promoter (RAW264-pNifty2-LUC). The ELAM1 promoter is proximal to five NF-KB sites and drives the expression of a luciferase reporter gene in response to nuclear translocation and activation of the NF-KB transcription factor in cells. As shown in Figure 8, the presence of a broad concentration to range of CpnlO did not alter the dynamics of TLR3-induced NF-icB activation in RAW264-pNifty2-LUC cells stimulated with Poly(I:C). Poly(I:C) is a synthetic analog of double-stranded RNA, a molecular pattern associated with virus infection which activates NF-KB via interaction with TLR3. is 6.2.2 Cpnl0 dose-responsively increases production of Type I IFNs in response to TLR3 and TLR4 ligation RAW264.7 cells were pre-incubated for 2 hours with CpnlO then stimulated with LPS or Poly(I:C) for 24 hours. At this point cell culture supernatant was collected and analysed for IFNc/ antiviral activity using a cytopathic effect reduction bioassay as 20 previously described (Hamilton et al., (1996) J Immunol 156(7):2553). As shown in Figure 9 below, stimulation through either TLR4 (LPS) or TLR3 [Poly(I:C)] for 24 hours in the presence of Cpnl 0 lead to an up-regulation of Type I IFNs. RAW264.7 cells were then seeded at 2.5 x 10 5 /ml in sterile 24 well plates and allowed to adhere for 16-20 hrs. Cells were pre-incubated in the presence of a titration of 25 CpnlO then stimulated with LPS (TLR2/4) or Poly (I:C) for 4 or 6 hrs. Cell lysates were collected and either frozen at -70oC or processed immediately for direct mRNA isolation using Dynabeads. mniRNA was reverse transcribed with oligo (dT) primers and Superscript III First-Strand Synthesis System for RT-PCR. The resultant cDNA was amplified in a PCR with mouse IFN 03 specific primers. To verify that equivalent 30 amounts of template were added to each reaction and to confirm uniform amplification, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was transcribed and amplified for each sample. PCR products were separated on agarose gels and visualized after ethidium bromide staining as shown in Figure 10.

WO 2007/006095 PCT/AU2006/000980 - 36 In addition to data from the mouse macrophage cell line RAW264.7, it was also demonstrated that human PBMC stimulated with Poly(I:C) show increased production of type I IFN (IFN-o~) in the presence of Cpnl10, as shown in Figure 11. 5 6.2.3 GroES, the E. coli homologue of Cpnl0, cannot augment Poly(l:C)-induced IFN-P3 production In order to determine the specificity of the Cpnl0-mediated increase in Poly(I:C) induced IFN-3 production, the E. coli CpnlO homologue, GroES, was tested. As shown in Figure 12, GroES did not modulate the production of IFN-j3 induced by Poly(I:C) 10 through TLR3. 6.2.4 Pre-incubation with CpnlO followed by a wash abrogates the dose-responsive increase in Poly(l:C)-induced IFN-0 production In LPS stimulation assays, pre-incubation with CpnlO followed by a PBS wash 15 prior to addition of LPS did not impact the ability of Cpnl 0 to modulate the activation of NF-icB. However, in the Poly(I:C) assay, pre-incubation of RAW264 cells with CpnlO followed by a PBS wash dramatically reduced the Cpnl0 dose-responsive increase in IFN-j3 production with Poly(I:C) stimulation as shown in Figure 13. 20 6.2.5 CpnlO modulation of a Poly (l:C)- or LPS-induced response requires positive feedback of the type 1 interferon pathway Mice with a null mutation in the IFNAR1 (interferon-associated receptor 1) component of the type 1 IFN receptor are characterized by a complete lack of antiviral responses corresponding to increased susceptibility to viral infection and a loss of 25 antiproliferative responses to IFNoV4 (Hwang et al., (1995) Proc. Natl. Acad. Sci. USA 92: 11284). IFNAR1 deficient mice (IFNAR1/-) have an absence of constitutive IFN activity and abnormalities in the proportions and responses of hemopoietic cells, including macrophages. An ex vivo assessment of the involvement of Cpnl 0 in an IFN 'priming' response 30 was performed using bone marrow derived macrophages (BMMs) isolated from wildtype (wt) or IFNAR1-/- mice. BMMs were isolated and activated with a panel of TLR agonists (Poly(I:C) - TLR3 or LPS - TLR4) in the presence of a dose titration of Cpnl0. Supernatants were collected after 24 hours and cytokine levels analysed using a BD Mouse Inflammation CBA and mouse IFN/3 ELISA kit. Results from these assays 35 indicate that a positive feedback response through the IFNAR1 receptor is necessary for WO 2007/006095 PCT/AU2006/000980 - 37 Cpnl0 modulation of both Poly (I:C)-induced IFNfl production (Figure 14) and LPS induced TNF-a production (Figure 15). These data, which link the IFN feedback pathway to Cpnl0-mediated activity, were further corroborated with in vivo results from a mouse endotoxaemia study. In this 5 murine model of sepsis, mice were pre-treated for 30 minutes with 100 gg CpnlO via i.v. administration prior to i.v. injection of 10 gg LPS. Serum was collected after 1.5 hours and analysed for pro-inflammatory cytokine production using a BD Mouse Inflammation CBA and IFN3 ELISA. A significant (p<0.05) reduction in serum TNFa levels in mice co-treated with Cpnl0 correlated with a significant (p<0.01) decrease in serum IFNO 10 levels as shown in Figure 16. 6.3 Discussion and Conclusions At least one exception to the pattern of Cpnl0-mediated NF-KB modulation involves activation of cells by the TLR3 ligand Poly(I:C). In this TLR3 system, Cpnl0 15 was found to have no effect on NF-KB activation in response to Poly(I:C) stimulation of cells. In addition, Cpnl0 was found to induce a synergistic increase in production of type I interferons in response to Poly(I:C). One explanation for this apparent anomaly is that Cpnl0 participates in the modulation of a priming or feedback loop response. For 20 example, Type I interferons have been shown to play important roles in the LPS regulated response either directly or indirectly (for example, through SOCS1). This is a significant development in understanding Cpnl 0 mechanisms of action in that it suggests Cpnl0 triggers the downregulation of pro-inflammatory cytokines such as TNFoa by dampening early cellular priming by type I IFN. 25 Example 7- Cpn10 modulation of Semliki Forest Virus (SFV) infection in mice This series of studies was undertaken to determine whether administration of Cpnl0 affected the lethality of Semliki Forest Virus (SFV) in a mouse model, and whether CpnlO modulates Type I IFN production in response to TLR activation. 30 The in vivo model involved a systemic infection of Semliki Forest Virus (SFV) for initial determination of modulation of the antiviral activity of type I IFNs. The model can be performed in neonatal mice where all organs including the brain are infected, causing lethality within 4-6 days depending on the dose, and therefore has the advantage of sensitivity and acuteness of infection. Alternatively the model can be tested in adult 35 mice that are less susceptible to the virus, due to type I IFN production. It is understood WO 2007/006095 PCT/AU2006/000980 - 38 that production of IFN within the first 24-48 hrs following virus infection results in decreased viral titres. This model is amenable to analyses of "chronic" responses including serum analyses and immune responses. The in vitro study included a series of assays to test the effect of priming of 5 macrophages on CpnlO modulation of cytokine production in response to TLR activation, including the comparison of freshly-isolated bone marrow macrophages from WT and IFNAR deficient mice. 7.1 Materials and Methods 10 Cpnl0 batch CH003 was used at 5.0 mg/ml in 50 mM Tris, and 150 nmM NaCl with endotoxin <0.01 EU/ml. Diluent formulation buffer comprised 50 mM Tris and 150 mM NaC1. Pam3cys and polyl:C was from Invivogen. Mice were C57BL/6. For the in vivo study, a pre-study involving viral titration was undertaken in mice to set appropriate virus batch and dosages. For the full study, 10 - 13 mice were used per 15is group, with 3 groups of mice per dose of virus. Groups were treated as follows: (A) virus only; (B) virus + conc.A Cpnl0; (C) virus+ conc.B Cpnl0. Neonatal mice about 6-9 days old were injected i.p. with CpnlO (or formulation buffer) and SFV and maintained with their mothers. In addition, adult mice (wt and IFNAR deficient) 6-8 weeks old were injected i.p. with SFV, with Cpnl0 administered i.p. every 12 hrs over the first week of 20 viral infection, and at doses as determined. For the in vitro study, the effect of macrophage priming on CpnlO modulation of cytokine production in response to TLR activation and comparison of WT and IFNAR deficient macrophages was undertaken. Bone marrow derived macrophages (BMM) sourced from WT and IFNAR deficient mice were treated with the TLR agonists 25 pam3cys (TLR2), polyl:C (TLR3), and LPS (TLR4) over a dose range of Cpnl0. 7.2 Results Data from the in vivo neonate viral infection study demonstrated a significant increase in survival of SFV-infected mice treated with CpnlO. The following groups of 30 6-9 day old neonate C57BL/6 mice comprised the study: Group A: SFV (n=13); Group B: SFV + CpnlO 20 tg (n=13); Group C: SFV + CpnlO 50 gg (n=13). Group B and C were injected i.p. with 20 and 50 pg of CpnlO, followed (3 hrs later) by injection of 50 pl SFV (30 x TCID50) to all three groups. Mice were housed with their mothers and handled carefully throughout the experiment. Pups were carefully WO 2007/006095 PCT/AU2006/000980 - 39 monitored at regular intervals (12/24 hr) for standard signs of health status including mobility, condition, behaviour, etc. At 72 hours 54% and 69% of 20 and 50 tg Cpnl0 treated mice were alive, compared to 15% survival in untreated mice (Figure 17). It was also noted that mice in 5 the highest dose group were moving around whilst the other two groups were very sick and lying on their sides. By 84 hours all mice treated with SFV only succumbed to the virus, whilst 31% of both groups B and C were alive. 7.3 Discussion and Conclusions 10 CpnlO administration prolonged survival after viral infection in a dose-dependent manner, as seen by the 72h data. At 96h post infection, 18% of mice injected with Cpnl0 survive, while all untreated mice were dead at 88 hr post-infection. Survival of 50% and 70 % of mice at 72 h post-infection in the two Cpnl0 treated groups, versus 18% in the untreated group, was significant given the massive dose of virus administered. It was also is noteworthy that this result was obtained after a single administration of CpnlO. These data suggest induction of antiviral protection by Cpnl0. Example 8- CpnlO associates with the CD14-independent LPS receptor cluster The plasma membrane of cells is composed of lateral heterogeneities, patches and 20 microdomains. These membrane microdomains or lipid rafts are enriched in glycosphingolipids and cholesterol and have been implicated in cellular processes such as membrane sorting and signal transduction. The inventors proposed that Cpnl0 may localise to the lipid raft during LPS signal clustering, by binding either directly to TLR4 or to one of the other participants of the cluster to disrupt signalling. 25 8.1 Materials and Methods Cell labeling for FRET. MonoMac 6 cells (a human monocytic cell line) were labeled with 100 ptl of a mixture of donor conjugated antibody (Cy3) and acceptor conjugated antibody (Cy5). For labelling of Cpnl0, an anti-CpnlO rabbit polyclonal antibody was 30 used. The cells were rinsed twice in PBS/0.02% BSA, prior to fixation with 4% formaldehyde for 15 min. The cells were fixed in order to prevent potential re organisation of the proteins during the course of the experiment. Confocal imaging. Cells were imaged on a Carl Zeiss, Inc. LSM510 confocal microscope (with an Axiovert 200 fluorescent microscope) using a 1.4 NA 63x Zeiss 35 objective. The images were analysed using LSM 2.5 image analysis software (Carl Zeiss, WO 2007/006095 PCT/AU2006/000980 -40 Inc.). Cy3 and Cy5 were detected using the appropriate filter sets. Using typical exposure times for image acquisition (less than 5 s), no fluorescence was observed from a Cy3 labelled specimen using the Cy5 filters, nor was Cy5 fluorescence detected using the Cy3 filter sets. 5 FRET measurements. FRET is a non-invasive imaging technique used to determine molecular proximity. FRET can occur over 1-10 nm distances, and effectively increases the resolution of light microscopy to the molecular level. It involves non-radiative transfer of energy from the excited state of a donor molecule to an appropriate acceptor (Wu and Brand (1994) Anal.Biochem. 218: 1-13). The rate of energy transfer is inversely 10 proportional to the sixth power of the distance, between donor and acceptor (Kenworthy and Edidin (1998) Journal of Cell Biology 142: 69-84; Kenworthy and Edidin (1998) in Gelb,M.H. (Ed.) Methods in molecular Biology. Humana Press Inc, Totowa, NJ pp 37 49). The efficiency of energy transfer (E) is defined with respect to r and Ro, the characteristic F6rster distance by: 15

E

= 1/[ 1 +(r/Ro) 6 ] [1] In the present study, FRET was measured using a method as previously described (Kenworthy and Edidin (1998) Journal of Cell Biology 142: 69-84; Kenworthy and 20 Edidin (1998) in Gelb,M.H. (Ed.) Methods in molecular Biology. Humana Press Inc, Totowa, NJ pp 37-49). Briefly, samples were labeled with donor and acceptor conjugated antibodies, and energy transfer was detected as an increase in donor fluorescence (dequenching) after complete photobleaching of the acceptor molecule. Cells labeled only with the 26ic-Cy3 probe were used in order to determine the minimum time 25 required to bleach Cy3. Cy3 was bleached by continuous excitation with an arc lamp using a Cy3 filter set for 5 min. Under these conditions, Cy5 was not bleached. FRET images were calculated from the increase in donor fluorescence after acceptor photobleaching by: 30 E(%) x 100 = 10,000 x [(Cy3 postbleach- Cy3 pre-bleach)/Cy3 postbleach] [2] The scaling factor of 10,000 was used in order to expand E to the scale of the 12 bit images. 35 WO 2007/006095 PCT/AU2006/000980 -41 8.2 Results and discussion In the first set of data shown in Table 1, FRET was used to determine the concentration of receptor molecules involved in LPS-induced cell activation (MonoMac6 cells) in lipid rafts. By performing FRET experiments, it was possible to investigate 5 whether CpnlO (batch P003-04 or CHOO3), Hsp60, E. coli GroES and other molecules were co-localising with lipid rafts. FRET was measured in terms of dequenching donor fluorescence after complete photobleaching of the acceptor fluorophore. Increased donor fluorescence after destruction of the acceptor indicated that donor fluorescence was quenched in the presence of the acceptor because of energy transfer. The energy transfer 10 efficiency in the system was tested using a positive control, that is, the transfer between mAbs to different epitopes on GM1 (ganglioside, a raft-associated molecule) molecules, showing that the maximum energy transfer efficiency (E%) was 37 1- 1.0. A negative control between FITC-GM1 and rhodamine-MHC was also used, which revealed no significant energy transfer (3 - 0.4). This background FRET value is thought to be 1is caused by random FRET as both species are present at high concentrations. Table 1. Energy transfer efficiency values between donor-acceptor pairs. Donor (Cy3) Acceptor (Cy5) E : AE (%) Unstimulated MM6 cells GM1 GM1 37 L 1.0 GM1 MHC class I 3 -0.4 GM1 CD14 34 2.0 GM1 TLR4 5 ± 1.5 GM1 Hsp60 6 1 0.5 GM1 GroES 7 ± 1.5 GM1 Cpnl0 15 ± 2 MM6 cells stimulated with LPS GM1 MHC class I 3 0.5 GM1 CD14 35 1.5 GM1 TLR4 32 1.8 GM1 Hsp60 8 ± 2.0 GM1 GroES 6 1.0 GM1 CpnlO 28 2.0 20 Energy transfer between different pairs was detected from the increase in donor fluorescence after acceptor photobleaching. Data represent mean + standard deviation of a number of independent experiments. Data presented in Table 1 demonstrate that CD14 resides in lipid rafts, but that TLR4 was not found to be associated with lipid rafts prior to LPS stimulation, and is 25 apparently recruited there after LPS stimulation.

WO 2007/006095 PCT/AU2006/000980 -42 The next set of data describes the proximity of CpnlO to the TLR4 cluster, again using FRET. In Table 2, the positive control was TLR4 with itself, and gave a maximum energy transfer efficiency (E%) of 36 L 2.0. 5 Table 2. Energy transfer efficiency values between donor-acceptor pairs Donor (Cy3) Acceptor (Cy5) E ± AE (%) Unstimulated MM6 cells TLR4 TLR4 36 2.0 Cpnl0 CD14 12 h 0.5 Cpnl0 Hsp70 9 ± 1.0 Cpnl0 Hsp90 6 ± 2.0 CpnO10 CXCR4 3 - 1.0 TLR4 Hsp60 5 1 1.0 CD14 Hsp60 6 - 0.5 Cpnl0 Hsp60 5 - 2.0 GroES CD14 8 1.0 GroES TLR4 7 ± 1.5 GroES Hsp70 6 - 1.0 GroES Hsp90 7 1.5 GroES CXCR4 4 - 2.0 MM6 cells stimulated with LPS CpnI0 TLR4 36 Cpnl0 CD14 32 ± 0.5 CpnlO Hsp70 24 1.0 CpnlO Hsp90 18 12.0 Cpnl0 CXCR4 12 1.0 TLR4 Hsp60 6 1.0 CD14 Hsp60 4 ± 2.0 CpnlO Hsp60 6 ± 1.5 GroES CD14 7 - 0.5 GroES TLR4 8 - 1.0 GroES Hsp70 7 ± 1.5 GroES Hsp90 8 ± 2.0 GroES CXCR4 3 + 1.0 Energy transfer between different pairs was detected from the increase in donor fluorescence after acceptor photobleaching. Data represent mean ± standard deviation of 1o a number of independent experiments. As shown in Table 2, Cpnl0 did not associate with Hsp70, Hsp90 or CXCR4 in absence of LPS, but demonstrated an association with these members of the LPS activation cluster after LPS stimulation. While the data demonstrating whether there is an association of CpnlO with TLR4 prior to LPS stimulation is not shown here, there is a 15is strong association of CpnlO with TLR4 upon LPS stimulation. These data also demonstrate that Hsp60 does not associate with TLR4, CD14 or lipid rafts prior to or following LPS stimulation of cells. Importantly, the E. coli WO 2007/006095 PCT/AU2006/000980 -43 homologue of Cpnl0, GroES, which is routinely used as a negative control in experiments testing the activity of Cpnl0 as an immune response modulator, also does not associate with the lipid raft or with other members of the CD14-independent LPS activation cluster. 5 Example 9- Cpnl0 interacts with TLR clusters and within lipid rafts at the surface of PBMC In order to determine whether endogenously produced Cpnl0 interacts at the surface of PBMC with TLRs, TLR-associated molecules and with components of lipid microdomains, the inventors used a FRET analysis using a fluorophore-labeled anti 10 CpnlO antibody, in response to LPS stimulation of freshly-isolated human adherent monocytes. Since no recombinant Cpnl0 was added to the cell culture prior to imaging, Cpnl0 recognized at the cell surface would have been exported from intracellular stores. 9.1 Materials and Methods 15 Cell labeling for FRET. PBMC were isolated from healthy donor blood using density gradient centrifugation over Ficoll-Hypaque and adherent cells prepared. Cells were washed in order to remove non-adherent cells. The remaining adherent cell monolayers (1-2 x 105 monocytes/well) were cultured in 24-well plates in serum-free medium (Gibco) supplemented with 0.01% L-glutamine and 40 g/ml gentamicin. An aliquot of 20 the enriched monocyte preparation was routinely assessed for purity by flow cytometry (>80% pure). Alternatively, monocyte-derived DC were cultured for 5 days from enriched adherent peripheral blood monocytes with GM-CSF and IL-4 (R&D Systems) according to the published protocol (Bender, A et al. 1996. JInmunol Methods 196:121 135) prior to the FRET assay. 25 Cell labeling for FRET analysis was performed essentially as previously published (Triantafilou, K 2001. Nat Immunol 2:338-345). Freshly-isolated human monocytes or monocyte-derived DC were stimulated with 100 ng/ml LPS (Re-LPS from S. minnesota, List Labs, CA), 10 ng/ml S. aureus LTA (kind gift from Thomas Hartung, Konstanz, Germany), 0.1 ptg/ml poly(I:C), 20 ng/ml imiquimod, 1 ptM CpG ODN 30 (Invivogen), 25 [tg/ml ssRNA purified from Coxsackievirus B3, or buffer control for 10 min, washed, and then labeled with a 1:1 mixture of donor-conjugated antibody (Cy3) and acceptor conjugated antibody (Cy5). Cells were then fixed to prevent potential reorganization of proteins. Antibodies. Antibodies used in FRET analysis included: CpnlO (Johnson, B. 2005. J 35 Biol Chem 280:4037-4047), Hsp70, CXCR4, TLR3, TLR7, TLR9 (Santa Cruz), TLR2 WO 2007/006095 PCT/AU2006/000980 -44 (Genentech), Hsp90 (Bioquote), CD14 (26ic, ATCC, from HB246 hybridoma), GM1 (GM1-1, Calbiochem, GM1-2b, North Star Bioproducts, Liverpool, UK), MHC class I (MCA115, Serotec), TLR4 (HTA125, HyCult). Antibodies were labeled with either Cy3 or Cy5 using FluoroLink labeling kit (AmershamPharmacia). 5 FRET measurements. Cy3 was excited with a helium/neon laser emitting at 543 nm, and Cy5 with a helium/neon laser emitting at 633 nm. Cells were imaged on a Carl Zeiss, Inc LSM510 META confocal microscope (with an Axiovert 200 fluorescent microscope) using a 1.4 NA 63x Zeiss objective. The images were analyzed using LSM 2.5 image analysis software (Carl Zeiss, Inc.). Cy3 and Cy5 were detected using the appropriate o10 filter sets. Using typical exposure times for image acquisition (less than 5 s), no fluorescence was observed from a Cy3-labelled specimen. Tracks were scanned sequentially with only one laser and the respective detector channel active per scan. FRET was measured in terms of dequenching of donor fluorescence after complete photobleaching of the acceptor fluorophore. The efficiency of energy transfer (E) is 15is defined with respect to r and Ro, the characteristic Forster distance by: E = 1/[1 + (r/Ro) 6 ] (29). This method of FRET measurement was previously described (30). 9.2 Results As shown in Table 3, endogenously-produced Cpnl0 was found to associate with 20 TLR4 and other members of the TLR4 signal complex after LPS stimulation. The identification of Cpnl0 interacting with lipid raft moieties prior to LPS stimulation may indicate its release by dead cells, or up-regulation due to physical manipulation of cells during purification. The demonstration of endogenous Cpnl0 within lipid raft domains suggests its mode of delivery to the cell surface and extracellular secretion.

WO 2007/006095 PCT/AU2006/000980 -45 Table 3. Endogenous Cpnl0 associates with lipid rafts and members of the TLR4 signaling complex on PBMC as determined by FRET Donor (Cy3) Acceptor (Cy5) E AE (%) Unstimulated monocytes GM-1 GM-1 38 4 1.0 MHC I GM-1 5 ± 1.5 CD14 GM-1 37 2.0 TLR4 GM-1 6 - 1.0 CpnI0 GM-1 20 1.5 TLR4 TLR4 37 1.0 CpnI0 CD14 10 1.2 Cpnl0 TLR4 10 h 1.0 CpnlO Hsp70 9 ± 1.2 CpnlO Hsp90 5 ± 1.0 CpnlO CXCR4 4 ± 1.5 LPS-stimulated monocy tes MHC I GM-1 4 ± 1.5 CD14 GM-1 36 4- 1.0 TLR4 GM-1 34 - 1.2 Cpnl0 GM-1 30 =- 2.0 Cpnl0 CD14 34 : 2.5 CpnlO TLR4 35 - 1.2 Cpn10 Hsp70 25 h 1.0 CpnlO Hsp90 20 ± 2.0 Cpnl0 CXCR4 16 ± 1.0 Data represent mean ± s.d. from several independent experiments. 5 The inventors also sought to determine whether Cpnl0 associates directly with other TLRs using FRET analysis and freshly isolated cells. FRET was measured in terms of dequenching of donor fluorescence after complete photobleaching of the acceptor fluorophore. As shown in Table 4, large dequenching was observed between CpnlO0 and 10 most TLRs (with the exception of TLR3) located both on the cell surface and within the endosome of monocyte-derived DC (MoDC) in the presence, but not the absence, of ligand. (Note that a positive FRET signal with TLRs 7 and 9 on MoDC most likely indicates the presence of a small number of pDC in the MoDC population of cells.) 15 20 WO 2007/006095 PCT/AU2006/000980 -46 Table 4. Cpnl0 associates with TLRs at the cell surface and in the endosome of human MoDC in the presence, but not the absence, of ligand, as determined by FRET. Acceptor (Cy5) Donor TLR2 TLR3 TLR4 TLR7 TLR9 (Cy3) E±AE (%) E±AE (%) E-AE (%) E±AE (%) E-AE (%) Neg Ctrl 8 ± 1.0 5 ± 0.2 8 0.8 4 - 0.4 5 L 1.0 TLR4 Pos Ctrl 36 - 1.0 a LTA 28 d- 2.0 6 ± 1.0 8 1.0 5 ± 0.6 5 ± 1.0 Poly(I:C) 9 1.2 7 ± 1.0 8 0.5 9 ± 2.0 8 - 1.0 LPS 7 1.0 5 ± 1.0 32 1.5 5 0.2 4 0.5 Viral ssRNA 9 1.5 12 ± 0.8 8 0.5 20 ± 2.0 15 1.0 Imiquimod 9 1.2 13 ± 1.0 9 1.5 21 ± 0.7 15 1.2 CpG ODN 8 1.0 12 ± 1.0 9 ± 1.5 14 ± 1.4 22 1.0 Energy transfer (E±AE (%) between different pairs was detected from the increase in donor fluorescence 5 after acceptor photobleaching. For each pair, the donor (Cy3) was CpnlO, except in the control experiment where the donor (Cy3) was TLR4; the acceptor (Cy5) was the TLR. FRET was calculated from the increase in donor fluorescence after acceptor photobleaching by: E%x100=10,000 [donor post-bleach donor pre-bleach)/donor post-bleach]. Data represent mean ± s.d. from several independent experiments. o10 Example 10- Effect of TLR ligation on Cpnl0 To determine the relationship between TLR ligation and Cpnl0, and in particular, to test whether Cpnl0 is an endogenous regulator of the immune system, the inventors examined whether endogenous CpnlO is induced by cell stress in the form of TLR ligation or cytokine activation. The inventors also examined whether Cpnl0 is released 15is from cells when subjected to appropriate stimuli, and whether CpnlO was able to limit the signal induced by ligands to other TLRs. 10.1 Materials and Methods Reagents. Recombinant human CpnlO was produced to GMP specifications by 20 BresaGen Limited (Adelaide, Aus) essentially as described previously (Johnson, B. 2005. J. Biol Chem 280:4037-4047). The purity of CpnlO was determined to be >99% by SDS PAGE, and showed the same molar activity as GroES in a GroEL-mediated rhodanese refolding assay (Brinker, 2001. Cell 107:223-233) (data not shown). For FACS analysis, a cysteine residue was engineered onto the C-terminus of Cpnl0 and labeled with 25 AlexFluor647 (Invitrogen) according to manufacturer's instructions. LPS contamination WO 2007/006095 PCT/AU2006/000980 -47 of CpnlO was determined by Endosafe assay (Charles River Laboratories) to be routinely <0.2 EU/mg protein. TLR ligands and cytokines included: E. coli LPS (strain 055:B5, Sigma), E. coli ultra-pure LPS (0111:B4 Sigma), S. aureus LTA, B. subtilis LTA, S. aureus PGN, B. subtilis PGN, zymosan cell wall from S. cerevisae, poly(I:C), imiquimod 5 R837, CpG ODN 1826 and ODN2216, GpC ODN1826 control, (all from Invivogen, San Diego, CA), recombinant mouse IFNy, (Chemicon), IL-1 3 (PeproTech), and recombinant human TNF-cc (Invivogen). Antibodies. Rabbit polyclonal antibodies were raised against Cpnl10 and affinity purified at CBio. Cytometric Bead Array (CBA) Flex Sets recognizing phosphorylated signal o10 proteins (both human and mouse) including ERK1/2 (T202/Y204), JNK1/2 (T183/Y185), p38/MAPKinase (T180/Y182), CD14, and FcBlock (CD16/CD32) were from BD. Transfection, Cell Stimulation and Promoter analysis. The pCAT/LUC-CPN promoter construct was provided by M. Ryan and N. Hoogenraad (La Trobe University, 15 Melbourne). RAW264.7 cells were transiently transfected using GeneJuice (Novagen). After 24 h cells were harvested and cell viability assessed by trypan blue dye exclusion. Cells were seeded into 24-well plates and heat shocked (43 0 C for 15 min (mild), 30 min (moderate), or 60 min (severe)) followed by recovery at 37 0 C or stimulated after 18 h. Cells were washed, harvested in Cell Culture Lysis Reagent (CCLR, Promega) and 20 firefly luciferase signal measured using the Luciferase Assay System (Promega) and the Wallac Victor 2 Multilabel Counter (Perkin-Elmer). Real-time PCR. RAW264.7 cells were seeded at 2.5 x 10 5 /ml in sterile 24 well plates and adhered for 16-20 hrs prior to stimulation. Replicate samples for each condition were assayed. mRNA was isolated using Dynabeads (Dynal) and reverse transcribed with 25 oligo (dT) primers and Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen). The resultant cDNA was amplified in duplicate in 10 pl qPCR reactions each containing 2.5 pl of a diluted (20%) cDNA template, 6.25 gl Platinum SYBR Green qPCR Supermix-UDG (Invitrogen) and 0.25 pl each of 10 gM sense and antisense primers. The reaction conditions were as follows: 95oC 2 mins, 40 cycles of 95 0 C 10 s, 30 60'C 15 s and 72 0 C 20 s with a final melt step 72-95oC for 50 s. The qPCR reaction was performed on the Rotor-Gene 3000 instrument (Corbett Research). Target gene expression was normalized to housekeeper controls and analysed as previously described (Livak, K.J., and T.D. Schmittgen. 2001, Methods 25:402-408). Primers: 18S sense CGG CTA CCA CAT CCA AGG AA (SEQ ID NO: 5), 18S antisense GCT GGA ATT ACC 35 GCG GCT (SEQ ID NO: 6); Cpnl0 sense GCC GAA ACT GTA ACC AAA GG (SEQ WO 2007/006095 PCT/AU2006/000980 -48 ID NO:7), Cpnl0 antisense CAG GCT CAA TCT CTC CAC TC (SEQ ID NO: 8); Pbgd sense CCT GGT TGT TCA CTC CCT GA (SEQ ID NO: 9), Pbgd antisense CAA CAG CAT CAC AAG GGT TTT (SEQ ID NO: 10). Quantitation of endogenous Cpn10 in cell culture supernatant, cell lysates, and patient 5 sera. Non-transfected RAW264.7 cells were treated as described , and culture supemratants concentrated. Cells were assessed for viability, pooled per condition (n=4), pelleted by centrifugation and resuspended in CCLR. Total cell protein content was quantified by modified Bradford assay (BioRad). Levels of Cpnl0 in cell supernatants and in extracts (25 pg per sample) were analyzed by ELISA (detection limit 0.195 10 ng/ml). Serum from clinical trial subjects was tested at study entry for levels of circulating Cpnl0 by ELISA. These trials were conducted according to GCP guidelines and written informed consent was obtained from each subject prior to sample testing. Trial protocols were approved by human ethics committees at local centers. RA W264.7-HIV-LTR-LUC Assay. The RAW264.7-HIV-LTR-LUC assay was 15is performed essentially as described previously (Johnson, B. 2005. J Biol Chem 280:4037 4047). Cells were pre-incubated with CpnlO or control buffer for 2 h followed by addition of a dose range of TLR ligand. In each assay, Cpn10 was tested in a concentration range of 25-100 pg/ml, and ligands were used at concentrations which elicited a sharp dose-response curve, i.e. E. coli LPS at 0.2 - 5 ng/ml, Ultra-Pure E. coli 20 LPS at 5-10 ng/ml, LTA and PGN at 10-100 ptg/ml, zymosan at 10 - 100 pg/ml, poly(I:C) at 10 -100 tg/ml, imiquimod at 1-10 tg/ml, and CpG ODN at 3.25 - 16.25 ptg/ml. Incubation times with each agonist were optimized to ensure sufficient signal over background. As a negative control for human Cpn10, the E. coli homologue of Cpnl0, termed GroES was routinely used (purified essentially as previously described (Brinker, 25 2001. Cell 107:223-233)). Note that the level of endotoxin contamination in CpnlO and GroES preparations and in TLR ligand reagents was known to be less than the level shown previously to induce HIV-LTR activation at the concentrations used in these assays with this cell line (Johnson, B. 2005. J Biol Chem 280:4037-4047). Human PBMC cytokine assays. PBMC were isolated from healthy volunteer blood by 30 buoyant density gradient centrifugation on Ficoll-Paque Plus (Amersham Biosciences). PBMC were pre-treated with Cpnl0 (or buffer control) for 1 h, followed by stimulation with agonist for 20 h at 37 0 C and 5% CO 2 prior to collection of culture supernatant. Cytokine levels were analyzed using CBA (BD) or ELISA (Bender MedSystems). Detection of protein phosphorylation. RAW264.7 or PBMCs were incubated with 35 CpnlO for 2 h, followed by LPS stimulation for 30 min, centrifuged and pellets lysed WO 2007/006095 PCT/AU2006/000980 -49 with 0.1% SDS in PBS. Lysates were boiled for 5 min, cooled, cellular debris pelleted by centrifugation, and supernatants assayed for protein concentration as above. Phosphorylated signal proteins were detected using BD CBA Flex Sets for p38, ERK1/2 and JNK1/2. Alternatively, RAW264.7 were treated with Cytofix/Cytoperm (BD) and 5 dual-stained for intracellular p38 and cell surface CD14. Samples were analyzed using the BD FACSArray Bioanalyzer with FCAP array software. Statistical analysis. Changes in promoter activity following cell stimulation were assessed using one way ANOVA and Tukey's Multiple Comparison Test comparing unstimulated to stimulated conditions at optimal agonist concentrations. Cpnl0 in subject 1o serum samples were tested for significance between groups using one-way ANOVA and Tukey's Multiple Comparison Post Test. 10.2 Results 15is 10.2.1. TLR ligation induces the CpnlO promoter RAW264.7 cells were transfected with a reporter construct where luciferase production was under the control of the Cpn10 promoter. Purified recombinant IFNy, TNF-ca and IL-lp3 were tested as non-TLR agonists. Cells treated with moderate heat shock (43 0 C, 30 min) demonstrated significant induction of the Cpn10 promoter at the 6 20 h recovery timepoint, with return to basal level by 18 h (Fig 18A). It was then established that TLR agonists dose-dependently induced the CpnlO promoter, with maximal activation observed after 20 hours (Fig 18A and 19C). Agonist concentrations were then optimized to induce maximal promoter response (Figure 18B-G). Comparison of responses to TLR and non-TLR agonists demonstrated a distinct 25 profile of Cpnl0 promoter activity (Figure 18H). A significant up-regulation of CpnlO was observed in response to ligands of TLR 2, 7 and 9, suggesting a correlation with the MyD88-dependent TLR signaling pathway. No significant up-regulation of the CpnlO promoter was observed using TLR ligands which can utilize the TRIF-dependent signaling pathway (TLR3 and 4). Furthermore, the non-TLR agonists IFNy, IL- 103 and 30 TNF-ca did not induce substantial up-regulation of the Cpnl0 promoter, indicating a certain degree of specificity in the transcriptional control of Cpnl 0. As another demonstration of TLR-induced CpnlO transcription, real-time PCR analysis was used to show that LTA stimulation of RAW264.7 cells results in concentration-dependent induction of Cpnl0 mRNA, with maximal induction at 18 h and 35 return to near baseline level by 24 h post-stimulation (Figure 181).

WO 2007/006095 PCT/AU2006/000980 - 50 10.2.2. Cpnl0 is released from cells following TLR ligation To examine whether Cpnl0 is released from cells when subjected to the appropriate stimuli, the inventors stimulated RAW274.7 cells with LTA and monitored 5 by ELISA the presence of endogenous Cpnl0, and Cpnl0 released by cells into the culture medium. Analysis of cell lysates revealed little change in intracellular Cpnl0 levels from LTA treated and control cells (Figure 19A). Analysis of the culture supernatants, however, revealed a 3-fold increase in soluble Cpnl0 after 30 h (Figure 19B) over unstimulated control cells. In addition, levels of extracellular Cpnl 0 produced o10 by stimulated cells correlated with the increases seen in CpnlO promoter activity over time (Figure 19C). These data indicate that a proportion of newly synthesized Cpnl0 produced under conditions of immune challenge is released by cells. Analysis of culture supernatants from cells (either RAW264.7 or pCAT/LUC-CPN-transfected RAW264.7 cells) exposed to mild, moderate or severe heat shock (HS) demonstrated little 15is accumulation of extracellular Cpnl0 by comparison with supernatant from cells stimulated with LTA (Figure 19D). These data suggest that Cpnl0 is induced by HS to assist in mitochondrial protein misfolding, while specific immune challenge leads to the extracellular accumulation of Cpnl 0. In order to gain evidence that Cpnl0 may be regulated in disease, the inventors 20 tested baseline serum levels of Cpnl0 in patients suffering from chronic inflammatory diseases and compared these to a cohort of healthy volunteers. As shown in Figure 19E, circulating levels of Cpnl10 in patients with rheumatoid arthritis were significantly higher than in patients with multiple sclerosis, psoriasis or in healthy subjects (1.32 ng/ml ± 1.41, n=23, 0.44 ng/ml -0.46, n=46; 0.55 ng/ml ± 0.52, n=25; 0.45 ng/ml ± 0.32, n=24, 25 respectively). Respective serum levels of CpnlO may therefore correlate with ongoing inflammation on an individual and/or disease level. Whether due to passive release following cell lysis or stimulated release following immune cell stimulation during inflammatory challenge, it is clear that Cpnl0 accumulates in the extracellular milieu, and that its export is enhanced with certain cell stimuli. 30 10.2.3. CpnlO limits the dynamics of TLR signaling The inventors examined whether recombinant Cpnl0 was able to limit the signal induced by ligands to other Toll-like receptors. Pre-incubation of this reporter cell line with an optimal concentration of Cpnl 0 for 2 h prior to stimulation with a variety of TLR 35 ligands, ranging from Gram-positive bacterial peptidoglycans (PGN) and lipoteichoic WO 2007/006095 PCT/AU2006/000980 - 51 acids (LTA) to synthetic RNA and DNA motifs, resulted in significant reductions in NF icB-induced luciferase activity by comparison with cells stimulated in the absence of exogenous Cpnl0. With the exception of the synthetic TLR3 ligand polyinosine polycytidylic acid (poly(I:C)), the presence of Cpnl0 in cell cultures stimulated with all 5 other tested TLR ligands resulted in 20-80% inhibition of luciferase activity (Figure 20A). These results indicate that Cpnl0 is able to modulate the strength of signal of the immune response generated by ligands to most TLRs. Stimulation of cells with LPS triggers both MyD88-dependent and -independent signaling cascades. The MyD88-dependent cascade is shared by all TLRs with the o10 exception of TLR3, and involves NF--cB and the mitogen-activated protein (MAP) kinases (MAPK), including p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). Both of these pathways culminate in regulation of the initiation and dynamics of an immune response. In order to elucidate the events by which Cpnl0 regulates both NF-icB activation and cytokine production following stimulation of cells, 15is the inventors analyzed the levels of phosphorylation of key proteins involved in the MAP kinase signal pathway. As shown in Figure 20B-D, Cpnl0 dose-responsively reduced the level of LPS-induced phosphorylation of p38, ERK1/2 and JNK1/2 in both a mouse macrophage cell line (RAW264.7) and in freshly isolated human PBMC. Since activation of the MAPK pathway is closely linked with induction of the inflammatory cascade of 20 cytokine production, these data demonstrate that Cpnl0-mediated changes in ligand induced cytokine production result from changes in the TLR signal cascade. To confirm the activity of CpnlO on production of cytokines by freshly-isolated human cells stimulated with a variety of TLR ligands, the inventors pre-treated PBMC from healthy donors with or without Cpnl0 for 1 h and then stimulated with a selected 25 range of TLR ligands for 20 hours. Cytokine levels in cell culture supernatants were then assayed using ELISA or cytometric bead array (CBA). As shown in Figure 20E, cytokine production induced by agonists to TLR2, TLR2/6 or TLR4 (PGN, LTA, Zymosan, LPS), including TNF-ca, IL-1j3, IL-6 and IL-10, was inhibited in the presence of CpnlO. Note that while CpnlO mediated a slight induction of LPS-induced IL-10 production, the data 30 demonstrate reduced IL-10 production in response to other TLR ligands. Similarly, stimulation of PBMC with agonists to TLR7 or 9 with imiquimod or CpG ODN in the presence of Cpnl0 led to reduced production of TNF-( and increased IFNou, by comparison with control cultures without CpnO0. 35 WO 2007/006095 PCT/AU2006/000980 - 52 10.3 Discussion This study uncovers a previously unidentified role of Cpnl0 as an endogenous regulator of the immune system. Stimulation of cells via the TLR system of receptors, but not through TNF-c, IFNy or IL-13 receptors, induces the Cpnl0 promoter and 5 production of Cpnl0 protein that can be measured in the extracellular medium. The addition of recombinant Cpnl0 dose-responsively limits TLR-driven cell activation, as assessed by NF-xB activation, MAPK phosphorylation, and production of cytokines by a murine cell line and by freshly-isolated human PBMC in vitro. These results demonstrating induction of Cpnl0 with immune insult, together with 10 data showing Cpnl0-mediated limitation of the magnitude of an inflammatory response, provides strong evidence that Cpnl0 is an essential member of a negative feedback pathway central to the immune response network. Example 11- CpnlO-induced modification of TLR4 expression upon LPS stimulation 15is The inventors sought to determine the effect of Cpnl0 on TLR4 expression in RAW264 cells in order to examine whether Cpnl0 affects the surface expression of TLR4 upon LPS stimulation 11.1 Materials and methods 20 LPS was sourced from E. coli (Sigma), anti-mouse TLR4/MD-2-biotin and Streptavidin-Phycoerythrin was sourced from eBioscience, and anti-mouse IFN-y was sourced from BD. Cells were cultured for the indicated period of time in suspension in the presence or absence of 100 gg/ml CpnlO. Cells were then transferred to 10 ml tubes, counted, 25 pelleted and resuspended in fresh culture medium. 100 tl of cell suspension was transferred to Eppendorf tubes (106 cells/tube). 4 hr Cpnl0 treatment and LPS stimulation was performed in the Eppendorf tubes kept in the incubator with gentle mixing every 15 mins. Cells were washed 3x with PBS/0.2% FBS. Anti-mouse TLR4 biotin (1 ptl in 50 ptl PBS/0.2% FBS) or control antibody (anti-mouse IFN-y-biotin) was 30 incubated with the cells on ice for 1 hr. The cells were washed 3x in 1 ml PBS/0.2% FBS and then blocked with 50 p1 PBS/10% FBS for 45 min at 4oC. Streptavidin-PE was then added at 1/100 dilution and incubated for a further 1 hr on ice. After 3 washes the cells were fixed in 1% paraformaldehyde in PBS and analysed on a FACS Caliber using Cell Quest software. 35 WO 2007/006095 PCT/AU2006/000980 - 53 11.2 Results Cpnl O incubated with RA W264 cells for 4 hr does not change TLR4 expression. TLR4 was readily detected on the surface of RAW264 cells using anti-mouse TLR4/MD-2 Biotin followed by Streptavidin-PE (Figure 21). The control antibody failed to show 5 significant staining (data not shown). Neither Cpnl0 treatment for 4 hr or control buffer treatment resulted in an alteration of TLR4 expression. Down-regulation of TLR4 by LPS and the influence of CpnlO. The addition of 2 ng/ml LPS caused slight reduction (Figure 22), and 20 ng/ml of LPS caused near complete loss (Figure 23) of TLR4 expression 2 hr post LPS addition. CpnlO incubation for 4 hr did 1o not significantly change the behaviour of TLR4 after LPS addition. When Cpnl0 treatment was extended to overnight, TLR4 expression was slightly reduced (Figure 24 and 25) compared to buffer-treated cells (Figure 24 and 25). The LPS-mediated reduction in TLR4 expression was slightly more pronounced in Cpnl 0-treated cells when the cells were given 2 ng/ml LPS (Figure 24). When the cells were treated with 20 ng/ml LPS, 15is TLR4 expression was essentially lost in all groups (Figure 25). 11.3 Discussion and conclusion The reduction in LUC activity mediated by 4 hr Cpnl0 treatment caused a 30 50% reduction in LPS-induced NF-icB activation. This effect is unlikely to be due to the 20 Cpnl0-mediated down-regulation of TLR4 expression as such treatment did little to change TLR4 expression levels. The down-regulation mediated by 2 ng/ml LPS was perhaps very slightly more pronounced after 4 hr CpnlO treatment, and was certainly more pronounced after overnight Cpnl0 treatment. These results suggest that Cpnl0 is able to change the dynamics of TLR4 expression following LPS addition. 25 Example 12- Cpnl0 limits the cellular response to a broad spectrum of TLR agonists The inventors undertook to document the breadth of Cpn10-mediated inhibition of NF-icB activation induced by a number of TLR ligands. 30 12.1 Materials and methods E. coli LPS 055:B5 was sourced from Sigma, and E. coli LPS 0111 :B4 Ultra-Pure (1 x 106 EU/mg), S. aureus lipoteichoic acid (LTA) (12.5 EU/mg), S. aureus peptidoglycan (PGN) (<0.125 EU/mg), B. subtilis lipoteichoic acid (LTA) (12.5 EU/mg), B. subtilis peptidoglycan (PGN) (0.25 EU/mg), S. cerevisae zymosan (<0.125 EU/ml), 35 Imiquimod R837, CpG ODN1826 (mouse),CpG ODN2216 (human), and GpC ODN1 826 WO 2007/006095 PCT/AU2006/000980 - 54 (non-stimulatory controls), were all sourced from Invivogen. Recombinant mouse IL-1/3 was sourced from R & D Systems, recombinant mouse IFNy and recombinant mouse TNFa were sourced from Chemicon. The cytoldkine bead array was sourced from BD. RAW264-HIV-LTR-LUC Bioassay. The bioassay was performed essentially as 5 described in Johnson, B. et al. 2005. JBiol Chem 280:4037-4047. In each assay, Cpnl0 was tested in a concentration range of 25-100 ptg/ml, and the stimulants used at concentrations which elicited a sharp dose-response curve, i.e. E. coli LPS at 0.2 - 5 ng/ml, Ultra-Pure E. coli LPS at 5-10 ng/ml, S. aureus and B. subtilis LTA and PGN at 10-100 pg/ml, S. cerevisae zymosan at 10 - 100 ptg/ml. Note that the level of endotoxin 10 contamination in both Cpnl0 preparations and in TLR ligands was known to be less than the level shown previously to induce HIV-LTR activation at the concentrations used in these assays using this cell line (Johnson, B. et al. 2005. JBiol Chemin 280:4037-4047). In data presented below, note that the read-out of stimulation of this cell line is described as activation of NF-icB on the understanding that HIV LTR is known to be highly 15is responsive to NF-icB activation and is therefore an indirect measure of activation of this transcription factor. Human Peripheral Blood Mononuclear Cell (PBMC) cytokine assays. PBMC were isolated from heparinized blood of healthy volunteers by buoyant density gradient centrifugation on Ficoll-Paque Plus (Amersham Biosciences). PBMC were used as 20 freshly-isolated cells, or alternatively stocks were stored in cryo-tubes in liquid nitrogen until use. PBMC were dispensed at in 200 pl/well at 8 x 10 5 viable cells/ml into 96-well tissue culture plates (Greiner Bio-One, Kremsmuenster, Austria). Cpnl 0 was added for 1 hr, followed by stimulation with agonist for 20 hrs at 37 0 C and 5% CO 2 prior to collection of culture supernates. Cytokine levels were analysed using commercially 25 available ELISA kits (R&D Sciences) and cytometric bead array (BD). Detection of phosphorylation levels of signal molecules. RAW264.7 or PBMCs were incubated with Cpnl0 for 2 h, followed by LPS stimulation for 30 min, centrifuged and pellets lysed with 0.1% SDS in PBS. Lysates were boiled for 5 min, cooled, cellular debris pelleted by centrifugation, and supernatants assayed for protein concentration as 30 above. Phosphorylated signal proteins were detected using BD CBA Flex Sets for p38, ERKl/2 and JNK1/2. Alternatively, RAW264.7 were treated with Cytofix/Cytoperm (BD) and dual-stained for intracellular p38 and cell surface CD14. Samples were analyzed using the BD FACSArray Bioanalyzer with FCAP array software. 35 WO 2007/006095 PCT/AU2006/000980 - 55 12.2 Results TLR agonist induced activation of HIV-LTR. The data represented in Figure 26 demonstrate the ability of Cpnl0 to regulate NF-wB activation in murine macrophage RAW264-HIV-LTR-LUC cells which were stimulated with a concentration range of 5 TLR ligands. We have assayed a broad range of ligands to the TLRs, including both UltraPure LPS (TLR4 only) and non-repurified LPS (described as stimulating both TLR2 and TLR4), LTA from two Gram-positive bacteria, B. subtilis and S. aureus, (TLR2), and PGN from both of the above Gram-positive bacteria (TLR2). In addition, cells were stimulated with zymosan, a preparation isolated from the cell wall of the yeast S. o10 cerevisiae, (TLR2/TLR6), and the synthetic double-stranded RNA, poly(I:C), which binds to and stimulates through TLR3. Cells were also tested after stimulation with CpG DNA (TLR9) or imiquimod (R837), a low molecular weight synthetic molecule which activates cells via the TLR7 MyD88-dependent pathway, in the presence of Cpnl0. Data is presented showing Cpnl0-induced modulation of NF-KiB activation following ligation 15 of four of the TLRs tested (TLR2, 4, 7, 9). Figure 27 depicts the maximal percent Cpnl0-induced inhibition of luciferase activity in RAW264-HIV-LTR-LUC cells stimulated by a variety of TLR ligands. While the response pattern is very similar for most ligands tested, with an average 50% inhibition of HIV-LTR activation, CpnlO0 does not appear to change TLR3-induced NF 20 KB activation in response to poly(I:C). Furthermore, Cpnl0 effected a limited NF-B inhibition of approximately 20% in cells activated by the yeast cell wall preparation zymnosan. The influence of CpnlO on phosphorylation of intracellular signal proteins. LPS stimulation of RAW264 cells activates several intracellular signaling pathways including 25 the IkappaB kinase (IKK)-NF-KB pathway, and three mitogen-activated protein kinase (MAPK) pathways: extracellular signal-regulated kinases (ERK) 1 and 2, c-Jun N terminal kinase (JNK) and p38. Further downstream, these signaling pathways activate a number of transcription factors including NF-kB and AP-1 which then coordinate the induction of genes encoding inflammatory mediators. In order to assess the influence of 30 Cpnl 10 on these signal systems, the inventors measured the levels of phosphorylated p 3 8, JNK1/2 and ERK1/2 in cells stimulated with LPS for 30 minutes, in the absence or presence of CpnlO. The inventors have shown that CpnlO dose-responsively limits the LPS-induced phosphorylation of each of these members of signaling pathways (Figure 28).

WO 2007/006095 PCT/AU2006/000980 - 56 To confirm the activity of Cpnl0 on production of cytokines by freshly-isolated human cells stimulated with a variety of TLR ligands, the inventors pre-treated PBMC from healthy donors with CpnlO for 1 h and then stimulated with a selected range of TLR ligands for 20 h. Cytokine levels in cell culture supernates were then assayed using 5 ELISA or cytometric bead array. As shown in Figure 29A-D, cytokine production induced by agonists to TLR2 or TLR4 (PGN, LTA, Zymosan, LPS), including TNF-ca, IL-1 3, IL-6 and IL-10, was reduced in the presence of Cpnl0. Similarly, stimulation of PBMC with agonists to TLR7 or 9 with Imiquimod or CpG (ODN2216) in the presence of Cpnl0 led to a reduced production of cytokines by comparison with control cultures 10 without Cpnl0, indicated by data in Figure 29E. Pre-incubation of CpnlO followed by wash does not impact the ability of CpnlO to limit the LPS-induced activation of NF-rcB. The inventors have previously determined that pre-incubation of RAW264-HIV-LTR-LUC cells for 2 hrs with Cpnl0 prior to stimulation with LPS optimizes the dose-responsive reduction in luciferase activity. They 15is have also now demonstrated that a 2-hr pre-incubation with Cpnl0 followed by a PBS wash prior to LPS stimulation does not alter the Cpnl0-mediated reduction in luciferase activity, as a measure of NF-icB activation, as shown in Figure 30. Non-TLR agonist inducedNF-icB activation. In order to further characterize the activity of Cpnl0, the inventors tested Cpnl0 modulation of a number of non-TLR agonists. As 20 part of this non-TLR programme, RAW264.7 cells were stimulated with 1-10 ng/ml of low endotoxin (2.24 EU/mg) recombinant mouse IFN-y for 6 hours in the presence of Cpnl0 (Figure 31). Cell supernatants were collected and analysed for TNF-a using ELISA. Cpnl0 was found to potentiate IFN-y -induced TNF-ca production. The marked synergistic increase in the production of TNF-c was enhanced when cells were pre 25 incubated with Cpnl0 for 2 hrs prior to IFN-y stimulation. Increased NF-icB-induced luciferase levels were also measured in lysates from RAW264-HIV-LTR-LUC cells stimulated with IFN-y in the presence of Cpnl 0 for 2 or 4 hours. 12.3 Discussion and conclusions 30 The inventors have demonstrated the ability of Cpn10 to regulate the dynamics of the macrophage response to a variety of TLR-specific ligands including TLR2, 4, 7 and 9, and hence the influence of Cpnl0 on the phosphorylation of signaling molecules upstream of NF-icB activation and cytokine production, namely members of the MAPK family of signaling proteins, including ERK, JNK and p38. The inventors have also WO 2007/006095 PCT/AU2006/000980 - 57 shown that Cpnl0 dose-responsively reduces levels of intracellular phosphorylated MAPKs in cells activated by LPS. The data presented in this example demonstrate that Cpnl0 dose-responsively regulates the dynamics of the innate immune response in macrophages stimulated in vitro 5 with a range of TLR ligands. The maximal level of Cpnl0-induced inhibition of NF-&B activation triggered by these molecules was approximately 80% following stimulation of the RAW264-HIV-LTR-LUC cell line with a TLR7 agonist (R837). On the other end of the scale, Cpn10 added at concentrations ranging between 10 and 100 pg/ml did not influence the dynamics of TLR2/6 engagement by the yeast cell wall preparation 10 zymosan by more than 20%. At least one exception to the pattern of reduced NF-icB activation by CpnlO involves activation by polyinosine-polycytidylic acid (poly(I:C)). Poly(I:C) is a synthetic analogue of double-stranded RNA, a molecular pattern associated with virus infection which activates NF-KB via interaction with TLR3. Rather than limiting the NF-B 15 activation signal, Cpnl 0 dose-responsively increases the production of type I interferons in response to this agonist. Example 13- Identification of cell surface receptors binding to Cpn10 conjugated to solid matrix 20 13.1 Materials and methods Isolation of receptors on host cells that bind Cpn10. Affinity columns (NHS-activated Hi-Trap) columns (AmershamPharmacia) were prepared using Cpnl0 (supplied by CBio Ltd, Batch CHOO3). Cpnl0 was dialysed into bicarbonate buffer pH 8.3 and conjugated 25 onto the column according to manufacturer's instructions. Human monocytes were lysed using NP-40 lysis buffer (0.05% w/v). Whole cell lysates were passed through the CpnlO affinity columns and unbound molecules were washed away with PBS. CpnlO-binding receptor molecules were eluted using b-octyl glucoside (b-OG) elution buffer (15 mM triethanolamine, pH 11.5, 140 mM NaC1, and 30 30 mM b-OG), neutralised with 1M 2-(N-morpholino)ethanesulfonic acid pH 5, and dialysed against PBS. As a control, cell lysates were also passed over a column onto which no protein had been conjugated. Eluents were concentrated using Centriprep YM-10 (Millipore), concentrated down to 1 ml and analysed by either SDS-PAGE (Figure 32) or 2D gel (Figure 33) 35 electrophoresis. For 2D gel electrophoresis the concentrated eluted solution was buffer- WO 2007/006095 PCT/AU2006/000980 - 58 exchanged using rehydration buffer (8 M urea, 2% CHAPS, 10 mM DTT, 0.2% Bio Lyte) (Biorad) prior to analysis. The bands or spots of interest were excised, tryptic digested and sent for MALDI-TOF analysis. Separation ofproteins by ID gel electrophoresis. The eluted solution was treated with 2 5 x SDS - PAGE reducing buffer (4 ml 10% SDS, 2.5ml 0.5M Tris - HC1 PH:6.8, 5g of Glycerol, 1 ml of 14.3M mercaptoethanol, and 5mg of Bromophenol blue) and placed in boiling water for 5 minutes. In order to run the samples Criterion Tris - HC1 Precast 4 20% gradient gels (Biorad) were used. The full range RAINBOW molecular weight marker (2 pl) was loaded in the first well and the remaining wells were loaded with 40 jil 10 of sample. The gel was then placed in the electrophoretic bucket and running buffer was added. The running buffer consisted of 0.025 M Tris, 0.2 M Glycine, 0.1% SDS, and was adjusted at pH 8.3. Electrophoresis was carried out for 50 minutes at 200V constant voltage. Following electrophoresis the gels were removed, fixed overnight with fixing buffer (40% ethanol, 10% acetic acid, 50% H20) and stained with Coomasie blue stain 15is (50% Coomasie blue (0.3 w/v), 25% methanol, 5% acetic acid, 20% H20) for 1.5 hours. The gels were finally destained by several washes with destain (10% ethanol, 10% acetic acid, 80 % H20. Separation ofproteins by 2D gel electrophoresis. A non-linear immobilized pH gradient (3-10 ReadyStrip IPG strip 11cm) was used as the first dimension. Aliquots of 200 gl of 20 sample were pipetted into the focusing tray and the IPG strip was placed over them with gel side down through the solution that contained sample and buffer. Mineral oil was placed over the IPG strip to avoid precipitation of the urea. The strips were allowed to 0 rehydrate for 12 hours under passive conditions at 20 C. The strips were then focused for approximately 52,000 v-hr at 6000 - 7000 volts at a constant 50 gA per strip. To prepare 25 the ReadyStrip IPG strips for the second dimension, they were removed from the focusing tray and equilibrated in 5 ml of buffer containing 50 mM Tris HC1, pH 8.8, 6 M urea, 2% SDS, 30% glycerol, 1% DTT. A second equilibration followed in 5 ml volume of the same buffer with 1.5% iodoacetamide substituted for the DTT. After equilibration, the ReadyStrip IPG strips were placed onto the Criterion gels (4 - 20% gradient) and 30 overlayed with 0.5% agarose with a trace of mercaptoethanol. The gels were run in the Criterion cell for 60 min at 200 V. Following electrophoresis the gels were removed, fixed overnight with fixing buffer ( 40% ethanol, 10% acetic acid, 50% H20) and stained with Coomasie blue stain (50% Coomasie blue (0.3 w/v), 25% methanol, 5% acetic acid, 20% H20) for 1.5 hours. The gels were finally destained by several washes with destain 35 (10% ethanol, 10% acetic acid, 80 % H20).

WO 2007/006095 PCT/AU2006/000980 - 59 13.2 Results Isolation of Cpn10- binding proteins by affinity chromatography and SDSPAGE electrophoresis. The inventors performed preliminary studies using the methodology as 5 described and identified several Cpnl0-binding proteins using mass spectrometry analysis, as shown in Table 5. Table 5. Identification of Cpn10-binding molecules using mass spectrometry Protein Name Accession No 78 kDa glucose-regulated protein precursor (GRP 78) GRP78 MESAU Serum albumin precursor ALBUBOVIN Elongation factor Tu-B EFTU2 PSEPK Annexin A2 ANXA2 HUMAN Triosephosphate isomerase TPISPANTR Profilin-1 PROF1 HUMAN 10 kDa heat shock protein mitochondrial CH10 HUMAN Ig gamma-1-chain C region IGHG1 _HUMAN Ig alpha 2 chain C region IGHA2 HUMAN alpha- 1-antitrypsin precursor A1AT HUMAN Peptidyl-propyl-cis-trans-isomerase A (Cyclosporin A-binding protein) PPIA MACMU 10 In order to verify these results as well as determine the identities of the proteins that were not identified, the inventors repeated the isolation of Cpnl 0-binding protein by affinity chromatography and analysed the eluted molecules by SDS-PAGE (Figure 32) as well as by 2-dimensional gel electrophoresis (Figure 33). Control experiments in which cell lysates were run over an affinity column to 15is which no protein had been conjugated demonstrated no protein bands on SDSPAGE (data not shown). 13.3 Discussion and conclusions This mass spectrometry data has enabled the identification of several proteins, 20 which could be potentially important for the binding and intracellular trafficking of Cpnl 0 to host cells. In particular, profilin, a small actin-binding protein, which regulates the dynamics of actin polymerization, appears to be a CpnlO-binding protein. Another molecule which could be important in regulating CpnlO responses is GRP78. GRP78 is a chaperone that could be involved in the trafficking of Cpnl 0. 25 WO 2007/006095 PCT/AU2006/000980 - 60 Example 14- The influence of Cpnl0 on the Ross River Virus antiviral response by cells stimulated with polyl:C in vitro The inventors were interested to test whether Cpn10 influences polyI:C-induced anti-viral resistance using a virus known to be highly sensitive to the antiviral effects of 5 IFNcdj3. 14.1 Materials and methods CpnlO. Cpnl 0 was dissolved in Tris-saline buffer pH7.6 and frozen on dry ice in aliquots and stored at -20 0 C. Aliquots were thawed prior to use. 10 PolyI:C. For the data shown in Figure 34, PolyI:C (supplied by Invivogen) was dissolved in sterile saline at 5 mg/mnil stored frozen at -20 0 C. Vials were thawed and diluted into medium. For buffer controls, the same volume and sterile saline was added to cell culture wells. For the data shown in Figure 35, PolyI:C was dissolved in sterile saline at 5 mg/ml, then aliquotted at 25 pl/500 pl and 62.5 [l of 100% ethanol (2.5 volumes) added 15is to precipitate the dsRNA. The tubes were stored at -70 0 C. On the day of the assay, aliquots were centrifuged at top speed (13,000rpm) for 30 min at 40 0 C. The pellet was washed once in 70% ethanol DEPC-treated distilled water, pelleted, the supernate removed and the pellet dried in the hood (about 15 mins) and resuspended in 100 p1 RPMI 1640. The recovery of dsRNA was determined to be about 50% as determined 20 using the RNA quantitation feature of the BioPhotometer (Eppendorf). All the dsRNA concentrations given in the figures assume a 50% recovery. Antiviral assay. RAW264.7 cells were grown as adherent cultures in flasks and scraped (i.e. not trypisinised) prior to seeding into 96-well plates. HeLa cells were trypsinised in the standard way prior to seeding. Cells were seeded in duplicate in a 96-well plate (5 x 25 103 for RAW264.7 cells and 10 4 for HeLa cells in 50 p1 medium per well). After 4 h, Cpnl0 was added (in 50 ptl diluted in medium) and after a further 30 mins polyl:C was added (in 50 p1 diluted in medium). The cells were then incubated overnight in the 96 well plates and then RRV was added (MOI=l for RAW264.7 cells, and MOI=10 for HeLa cells in 50 il). After 3 days, the cells were fixed, stained with crystal violet, 30 washed, dried and dye extracted with 100% methanol and read at A595 mn as described (Antalis et al, J Exp Med 1998, 187(11):1799). 14.2 Results The effect ofpolyl:C on RA W264.7 cells. Initially polyl:C was titrated into RAW264.7 35 cells in the range of 0 - 100 pg/ml). Concentrations of polyl:C >5-10 g/ml resulted in WO 2007/006095 PCT/AU2006/000980 -61 cells showing clear signs of toxicity with cells rounding up and growing poorly over the three day assay period. No such toxicity was observed for HeLa cells (Figure 34). Cpnl0 and polyl:C. Titrations were established to determine the dose required for induction of anti-viral resistance for RAW264.7 cells and HeLa cells. Then, using an 5 appropriate concentration range of polyl:C, the hypothesis was tested as to whether Cpnl0 increased the antiviral activity of dsRNA. As shown in Figure 35, neither RAW264.7 cells nor HeLa cells showed any difference in their antiviral resistance in the presence or absence of CpnlO at the concentrations of polyl:C and CpnlO tested over this three day assay measuring cell viability. 10 14.3 Discussion and conclusions In this study, Cpnl0 did not influence synthetic dsRNA-induced antiviral resistance against alphavirus-induced CPE. The data presented here does not support the view that Cpn10 may influence signaling by dsRNA. dsRNA can signal via TLR3, PKR, 15 RIG-1/mda-5 and/or ATF-2/c-Jun, although TLR3 is believed to be the major sensor of extracellular dsRNA, with the other signaling pathways triggered by cytoplasmic dsRNA. Example 15- Recombinant Cpnl0 interacts at the cell surface with APC 20 The inventors considered the means by which extracellular Cpnl0 might modulate an immune response. To identify which leukocyte subpopulations of cells bind Cpnl0, the inventors fluorophore-tagged Cpnl0 at a C-terminal cysteine residue and demonstrated that it retained equivalent chaperone and immunomodulatory activity to wild type Cpnl0 in vitro (data not shown). Upon incubation of labeled Cpnl0 with 25 PBMC at 4oC, together with a panel of antibodies to identify separate leukocyte subpopulations, it was demonstrated that Cpnl0 interacts most strongly with APCs, specifically myeloid DC (CD3"CD41OCD14-CDllc+), plasmacytoid DC (CD3" CD41OCD14-CD 11 c l w ) and monocytes (CD41OWCD14), with lower affinity to T cells (Figure 36A). When PBMC were stimulated with LTA, there was an approximate 1.6 30 fold increase in the level of fluorescent Cpn1 0 binding to the surface of CD 14 + cells by 4 h, by comparison with unstimulated CD14 cells (Figure 36B). These data suggest that extracellular Cpnl0 exerts its biological activity on APCs, key regulatory cells of the innate immune system. The inventors also followed the uptake pathway of fluorescent CpnlO into 35 immune cells by confocal microscopy. When human pDC or mouse macrophages were WO 2007/006095 PCT/AU2006/000980 - 62 incubated with fluorescent Cpnl0, together with reagents to identify intracellular compartments, it was demonstrated that CpnlO was rapidly taken up and trafficked to the acidified intracellular vesicles without entering the cytosol or mitochondria (Figure 36C). These data show that Cpnl0 protein associates with immune competent cells and is 5 concentrated in areas that signal the presence of TLR activating motifs. Example 16. Compositions for treatment In accordance with the best mode of performing the invention provided herein, specific preferred compositions are outlined below. The following are to be construed as 10 merely illustrative examples of compositions and not as a limitation of the scope of the present invention in any way. Example 16(a) - Composition for Parenteral Administration A composition for intramuscular injection could be prepared to contain 1 ml sterile 15 buffered water, and 1 mg of a suitable compound. Similarly, a composition for intravenous infusion may comprise 250 ml of sterile Ringer's solution, and 5 mg of a suitable compound. Example 16(b) - Injectable Parenteral Composition 20 A composition suitable for administration by injection may be prepared by mixing 1% by weight of a suitable compound in 10% by volume propylene glycol and water. The solution is sterilised by filtration. Example 16(c) - Capsule Composition 25 A composition of a suitable compound in the form of a capsule may be prepared by filling a standard two-piece hard gelatin capsule with 50 mg of the agent or compound, in powdered form, 100 mg of lactose, 35 mg of talc and 10 mg of magnesium stearate. Example 16(d) - Eye Drop Composition 30 A typical composition for delivery as an eye drop is outlined below: Suitable compound 0.3 g Methyl Hydroxybenzoate 0.005 g Propyl Hydroxybenzoate 0.06 g Purified Water about to 100.00 ml. 35 WO 2007/006095 PCT/AU2006/000980 - 63 The methyl and propyl hydroxybenzoates are dissolved in 70 ml purified water at 75 0 C, and the resulting solution is allowed to cool. The suitable compound is then added, and the solution sterilised by filtration through a membrane filter (0.22 pm pore size), and aseptically packed into sterile containers. 5 Example 16(e) - Composition for Inhalation Administration For an aerosol container with a capacity of 20-30 ml: a mixture of 10 mg of a suitable compound with 0.5-0.8% by weight of a lubricating agent, such as polysorbate 85 or oleic acid, is dispersed in a propellant, such as freon, and put into an appropriate 10 aerosol container for either intranasal or oral inhalation administration. Example 16(f) - Ointment Composition A typical composition for delivery as an ointment includes 1.0 g of a suitable compound, together with white soft paraffin to 100.0 g, dispersed to produce a smooth, 15 homogeneous product.

Claims (38)

1. A method for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, wherein said method comprises administering an effective amount of chaperonin 10, wherein Toll-like receptor signalling involves 5 association of the chaperonin 10 with a Toll-like receptor in an activation cluster.

2. A method for modulating Toll-like receptor signalling in a subject, or in at least one cell, tissue or organ thereof, wherein said method comprises administering an effective amount of at least one antagonist of chaperonin 10, wherein Toll-like receptor signalling involves association of the chaperonin 10 with a Toll-like receptor in an 10 activation cluster, and wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster.

3. The method according to claim 1 or claim 2, wherein the activation cluster comprises chaperonin 10, a Toll-like receptor, and optionally, at least one other molecule. is

4. The method according to claim 3, wherein the at least one other molecule comprises a Toll-like receptor agonist.

5. The method according to any one of claims 1 to 4, wherein the activation cluster comprises chaperonin 10, TLR2 and lipoteichoic acid (LTA).

6. The method according to any one of claims 1 to 4, wherein the activation 20 cluster comprises chaperonin 10, TLR3 and double-stranded RNA.

7. The method according to any one of claims 1 to 4, wherein the activation cluster comprises chaperonin 10, TLR4 and LPS.

8. The method according to any one of claims 1 to 4, wherein the activation cluster comprises chaperonin 10, TLR7 and single-stranded RNA. 25

9. The method according to any one of claims 1 to 4, wherein the activation cluster comprises chaperonin 10, TLR9 and DNA comprising a CpG motif.

10. The method according to any one of claims 1 to 9, wherein the chaperonin 10 comprises the polypeptide sequence as set forth in SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3. 30

11. The method according to any one of claims 1 or 3 to 9, wherein the chaperonin 10 is administered in the form of a polynucleotide encoding chaperonin 10.

12. The method according to claim 11, wherein the polynucleotide comprises the sequence as set forth in SEQ ID NO:4.

13. The method according to any one of claims 1 to 12, further comprising the 35 administration of at least one additional agent. WO 2007/006095 PCT/AU2006/000980 - 65

14. The method according to claim 13, wherein the at least one additional agent is an immunomodulator selected from the group comprising IFNca or IFN3.

15. A method for treating or preventing a disease or condition in a subject, wherein said method comprises administering to the subject an effective amount of 5 chaperonin 10, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition.

16. A method for the treatment or prevention of a disorder in the subject, wherein 10 said method comprises administering to the subject an effective amount of at least one antagonist of chaperonin 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or condition. s15

17. The method according to claim 15 or claim 16, wherein the disease or condition is selected from the group comprising viral or bacterial infections, acute or chronic inflammatory diseases including septic shock, inflammatory bowel disease, arthritis, psoriasis, heart disease, atherosclerosis, chronic pulmonary disease, cachexia, multiple sclerosis, GVHD and cancer. 20

18. The method according to any one of claims 15 to 17, wherein the chaperonin 10 regulates LTA-induced TLR2 signalling.

19. The method according to claim 18, wherein the chaperonin 10 modulates TLR2-induced immunomodulator production and/or secretion.

20. The method according to any one of claims 15 to 17, wherein the chaperonin 25 10 regulates double-stranded RNA-induced TLR3 signalling.

21. The method according to claim 20, wherein the chaperonin 10 modulates TLR3-induced immunomodulator production and/or secretion.

22. The method according to any one of claims 15 to 17, wherein the chaperonin 10 regulates LPS-induced TLR4 signalling. 30

23. The method according to claim 22, wherein the chaperonin 10 modulates TLR4-induced immunomodulator production and/or secretion.

24. The method according to any one of claims 15 to 17, wherein the chaperonin 10 regulates viral single-stranded RNA-induced TLR7 signalling.

25. The method according to claim 24, wherein the chaperonin 10 modulates 35 TLR7-induced inmnunomodulator production and/or secretion. WO 2007/006095 PCT/AU2006/000980 - 66

26. The method according to any one of claims 15 to 17, wherein the chaperonin 10 regulates CpG motif-induced TLR9 signalling.

27. The method according to claim 26, wherein the chaperonin 10 modulates TLR9-induced immunomodulator production and/or secretion. 5

28. The method according to any one of claims 15 to 27, further comprising the administration of at least one additional agent.

29. The method according to claim 28, wherein the at least one additional agent is an immunomodulator selected from the group comprising IFNa or IFNJ3.

30. A composition when used for the treatment or prevention of a disease or 10 condition, the composition comprising chaperonin 10 together with at least one pharmaceutically acceptable carrier, diluent or adjuvant, wherein the chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition. 15is

31. The composition according to claim 30, further comprising at least one agonist of a Toll-like receptor and/or at least one immunomodulator.

32. A composition when used for the treatment or prevention of a disease or condition, the composition comprising at least one antagonist of chaperonin 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation 20 cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or condition.

33. .A use of chaperonin 10 for the manufacture of a medicament for the treatment or prevention of a disease or condition, wherein the chaperonin 10 associates with a Toll 25 like receptor in an activation cluster, and wherein formation of the activation cluster is associated with initiation, enhancement and/or maintenance of an immune response to the disease or condition.

34. A use of an antagonist of chaperonin 10 for the manufacture of a medicament for the treatment or prevention of a disease or condition, wherein the antagonist prevents 30 chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with establishment and/or progression of the disease or condition.

35. A method for modulating the production and/or secretion of one or more immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said 35 method comprises administering an effective amount of chaperonin 10, wherein the WO 2007/006095 PCT/AU2006/000980 - 67 chaperonin 10 associates with a Toll-like receptor in an activation cluster, and wherein formation of the activation cluster is associated with modulation of the production and/or secretion of the one or more immunomodulators.

36. A method for modulating the production and/or secretion of one or more 5 immunomodulators in a subject, or at least one cell, tissue or organ thereof, wherein said method comprises administering an effective amount of an antagonist of chaperonin 10, wherein the antagonist prevents chaperonin 10 associating with a Toll-like receptor in an activation cluster, and/or prevents signalling by the activation cluster, and wherein formation of the activation cluster is associated with modulation of the production and/or to secretion of the one or more immunomodulators.

37. The method according to claim 35 or claim 36, wherein the immunomodulator is selected from the group comprising TNF-cx, IL-1p3, IL-6, IL-10, IL-12 or a type I interferon.

38. The method according to claim 37, wherein the type I interferon is IFNo or 15 IFNp.